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Abstract 
 
Objective: Many cancer patients suffer from depression after diagnosis of cancer and 
depression continues during cancer treatment and post-treatment procedure. Continuation of 
untreated depression may increase hospitalisations, nonadherence to treatment and decreased 
survival time of cancer patients. Antidepressants are commonly used for the pharmacological 
treatment of depression. Concerns have been raised about the possibility of inadequate 
prescribing of these drugs and the risk of drug-drug interactions when prescribed to cancer 
patients by doctors other than psychiatrists. This study had two main aims: 1) to 
systematically review and meta-analyse the prevalence of antidepressant prescriptions to 
cancer patients as reported in the literature and to explore whether there are differences by 
study or patient characteristics; 2) to use a retrospective case-control study design to describe 
the antidepressant prescribing practices for cancer and non-cancer hospital inpatients at an 
Australian tertiary hospital. 
Methods: AIM 1: The systematic literature search was undertaken according to Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methods. The 
keywords, ‘antidepressants’, ‘prescription’, ‘psychotropic’ and ‘cancer’ were used in the 
databases including PubMed, Embase, Web of Science, Scopus and psychINFO. Pooled 
estimate of the prevalence of antidepressants to cancer patients (95% Confidence Interval) 
reported in the studies were determined by using Comprehensive meta-analysis software 
(Version 3 by Borenstein, Biostat, Englewood, New Jersey, US, 2015). Type, dose and 
follow-up of antidepressants, cancer patient characteristics and their setting, place and 
duration of study and prescriber details were extracted for the review from each study. 
Quality (low quality to high quality ranged from 1-4) and risk of bias (no risk to high bias 
risk ranged from 0-4) were assessed to rate the quality of the articles included in the meta-
analyses. This review identified the lack of research and knowledge gaps in Australia.  
AIM 2: To address these gaps, a retrospective case-control study was undertaken in a tertiary 
hospital. Inpatients diagnosed with cancer within the past 12 months and prescribed 
antidepressants were considered as ‘cases’. Age and gender matched inpatients without 
cancer history prescribed antidepressants were included as ‘controls’. Patient medication 
charts, clinical and socio-demographic records were abstracted from the hospital database 
system. Conditional logistic regression was used to compare cases and controls according to 
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their socio-demographic characteristics, clinical status and their antidepressant treatment 
profile  by presenting odds ratios, 95% confidence intervals and p values (<0.05). 
Results: Study 1: The search conducted for the review and meta-analysis discovered 1537 
articles published between 1979 and February 2015 of which 38 met the inclusion criteria. 
These articles were reviewed in full for data extraction and meta-analyses. Across all studies, 
the pooled prevalence rate of prescribing antidepressants to cancer patients was 15.6% (95% 
CI= 13.3-18.3). Prescriptions were significantly less common reported in studies from Asia 
(7.4%; 95% CI= 4.3-12.5). Antidepressant prescriptions were more common in female 
(22.6%; 95% CI= 16.0-31.0) or breast cancer patients (22.6%; 95% CI= 16.0-30.9). Selective 
serotonin reuptake inhibitors (SSRIs) were the most frequently prescribed antidepressants. 
General practitioners and psychiatrists, followed by oncologists, were identified as the major 
providers of antidepressant prescriptions to cancer patients. Only very few studies reported 
the exact dose (n= 3), or the length of time (n= 3) drugs were prescribed for or detailed the 
follow-up regimens after the antidepressants were prescribed. Only one study was conducted 
in Australia and further research to determine the prescription characteristics of 
antidepressants to cancer patients is needed.  
Study 2: Data from 75 cancer and 75 non-cancer inpatients were extracted between January 
2014 and July 2015. Antidepressants were prescribed for the treatment of depression (n= 50 
vs n= 59) or other mental health problem including anxiety (n= 8 vs n= 11) to cancer and 
non-cancer patients, respectively. The remaining cancer and non-cancer patients (n= 17 vs n= 
5) were prescribed antidepressants for unidentified reasons. Mirtazapine (n= 11) was the 
antidepressant most commonly prescribed for the treatment of depression to cancer inpatients 
followed by duloxetine (n= 9) and escitalopram (n= 8).  Desvenlafaxine (n= 15) was the most 
commonly prescribed to non-cancer inpatients, followed by mirtazapine (n= 11). Cancer 
patients were more commonly prescribed the recommended daily dose of antidepressants 
(40.68%, n= 24/59 cancer patients; 38.67%, n= 29/75 non-cancer patients). Significant 
differences in several sociodemographic and clinical variables were documented between 
cases and controls.  Four cancer patients and three non-cancer patients had documented 
adverse side-effects from antidepressants. About one-third of cancer patients (n= 23) and 
more than one-fourth non-cancer patients (n= 18) had been prescribed simultaneously 
medicines with potential drug-drug interaction with their prescribed antidepressant.  From 
data that could be extracted from this hospital’s pharmacy database and clinical records there 
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appeared to be a lack of formal prescribing follow-up regimens or the clinical expertise of the 
prescriber of antidepressants. 
Conclusions: There is considerable variation in the prescribing patterns of antidepressants 
across the world, with few studies reporting robust data on exact dose or follow-up regimens. 
The retrospective case-control study showed that besides depression antidepressants are 
commonly prescribed for other mental problems including anxiety or unidentified reason to 
both cancer and non-cancer patients. A number of the aspects that are limitations of the 
present study such as antidepressant dosing variations, incomplete follow-up and prescriber 
information are important aspects of prescribing requiring further study. Prospective studies 
that describe antidepressants prescribing to cancer patients, monitor details of reasons for 
prescribing, the expertise of the health care providers involved, and the follow-up 
arrangements are needed to ascertain whether patients are being treated according to best 
guidelines available for the prescribing of antidepressants for the general population. Such 
study may help to develop nation-wide hospital guidelines for the prescribing of 
antidepressants in cancer patients and improve clinical outcomes in this vulnerable patient 
group. 
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Chapter 1: Introduction 
 
1.1 Depression in cancer patients 
 
Cancer is a major reason for prolonged illness, disability and premature death (AIHW, 2012). 
More than 120,000 people are newly diagnosed with cancer each year in Australia (AIHW, 
2015). Patients often face physical and psychological distress after a diagnosis of cancer; this 
distress often continues during the treatment procedures and throughout the survival period 
(NHMRC, 2003). However, many cases of depression remain unidentified. Sometimes health 
care professionals cannot easily detect the depression of cancer patients because it is difficult 
to differentiate the symptoms caused by the cancer or the treatment and mood disorders 
(Raison and Miller, 2003). Research has shown that continuation of untreated depression may 
cause risks for the survival of cancer patients (Faller et al., 1999, Olver and Burrows, 2007 & 
Hert et al., 2011). 
Studies that reviewed the prevalence of depression in cancer patients showed that the 
prevalence of depression in cancer patients varies depending on cancer type and patients 
setting. A review of 46 studies (1966-2000) showed that the prevalence of major depressive 
disorder ranged from 5% to 26% diagnosed by the Hospital Anxiety and Depression Scale 
(HADS) (Hotopf et al., 2002). Another review during the same time period (1965-2002) of 
92 studies on depression and type of cancer found that depression rate was highly associated 
with the type of cancer including oropharyngeal (22%–57%), pancreatic (33%–50%), breast 
(1.5%–46%), or lung (11%–44%) cancers (Massie, 2004). According to the patient setting 
and limitation of previous reviewed studies (including response rate of patients, quality of 
studies), a recent review which only included very high quality studies (n= 15, 1950-2012) 
showed that patients in palliative care (7%-49%) were diagnosed with higher prevalence rate 
of depression compared to other settings including inpatients (4%-14%), outpatients (5%-
16%) or both (4%-11%) (Walker et al., 2012). 
1.2 Prevalence of depression in cancer patients in Australia  
      
Two large studies have been identified that aimed to determine the prevalence of depression 
in cancer patients in Australia. Both studies used the HADS in cancer patients which is a 
valid test to detect severity and caseness of depression (Bjelland et al., 2002). A large 
population based cross-sectional study was undertaken to determine the prevalence of 
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depression in long-term adult cancer survivors (≥5 years) diagnosed in 1997 and who 
survived after 2002 (Boyes et al., 2009). Of these, 4% (n= 35/863) were diagnosed with 
depression which was a similar level of depression to general population in Australia 
(Australian Bureau of Statistics, 1998). Another nationwide prospective cohort study from 
2002-2006 in ovarian cancer showed that 5.9% (n= 47/798) of patients were suffering from 
depression (Price et al., 2010) which was somewhat higher than the general female 
population (5.1%, n= 50,790/995,900) in Australia (Australian Bureau of Statistics, 2008).  
A number of studies (n= 3) showed that the prevalence of depression was high at the 
diagnosis of cancer and the following six months post diagnosis. Stafford et al. (2015) found 
that 33.3% (n= 35/105) of breast or gynaecologic cancer patients were diagnosed with 
depressive symptoms using the HADS and the prevalence rate of depression (22%, n= 
23/105) decreased two years after diagnosis of cancer. Previously, Gallagher et al. (2002) 
identified that 43% (n= 84/195) of breast cancer patients reported the psychological distress 
two months and six months post-diagnosis of cancer using the General Health Questionnaire-
12 (GHQ-12). In some instance, prevalence rate of depression changes with cancer treatment. 
A prospective observational study from 2008-2009 in people with head and neck cancers 
showed that 15% of patients (n= 15/102) faced mild to severe depression before cancer 
treatment which doubled (n= 30/102) after treatment determined by the HADS (Neilson et 
al., 2010). Overall, the findings of these studies in Australia showed the prevalence rate of 
depression appears to peak within 12 months of cancer diagnosis.    
Another three studies conducted research on prevalence of depression of cancer patients 
according to their physical status. A large cohort study was conducted on adults (aged 45 
years or older) in Australia 2006 to 2008 and 16.1% (n= 14,380/89,574) of the participants 
were cancer survivors. This study showed that cancer patients who needed help for daily 
tasks were at higher risk (Odds ratio (OR) 5.81; 95% Confidence Interval (CI) 4.88–6.91) of 
psychological distress diagnosed by the Kessler Psychological Distress Scale (K 10) 
compared to cancer patients without disability (1.14; 95% CI 1.04–1.24) (Banks et al., 2010). 
In palliative care, 45.8% (n= 121/266) of cancer patients were diagnosed with possible 
symptoms of depression determined by the HADS (O’Connor et al., 2010). Another study 
showed that cancer patients (n= 115) with emotional and physical problems were more likely 
to also be highly distressed as identified through routine distress screening measurement (Lee 
et al., 2010).  
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Overall, it has been identified that the prevalence of depression of cancer patients in Australia 
was high from the time of diagnosis of cancer to one year after the diagnosis of cancer. 
1.3 Treatments of depression in cancer patients 
 
European guidelines have been developed for the evidence-based management of depression 
of cancer patients in palliative care. The guidelines recommend the steps that should be 
followed in the prevention; detection, diagnosis and assessment; and treatment of depression 
(Rayner et al., 2011). In contrast, Australian and New Zealand Clinical Practice Guidelines 
for the treatment of depression by specialist services more generally (not specifically for 
cancer patients) summarises that it is necessary to consider assessment, treatment and 
management issues for the treatment of depression (Ellis et al., 2003 & Ellis, 2004). No 
specific guidelines for the treatment of depression in cancer patients are available in 
Australia. However, the following steps may be considered for the treatment of depression in 
cancer patients according to Australian and New Zealand Clinical Practice Guidelines- 
1.3.1 Assessment  
 
Before prescribing pharmacological therapy or medications, prescribers should check and 
identify risk factors of cancer patients including suicidal ideation or likelihood of harm to 
others; subtype, severity and duration of depression; family history and comorbidities of 
patients; availability or absence of social support, concurrent life stresses, chronic pain, and 
performance status (Ellis et al., 2003; Ellis, 2004 & Rayner et al., 2011).  
1.3.2 Treatment 
 
Four reviewed studies summarised the evidence of benefit of antidepressants for the 
improvement of psychological distress in cancer patients (Hennaux and Razavu, 1990; 
Raison and Miller, 2003; Laoutidis and Mathiak & 2013 Walker et al., 2014). 
Antidepressants should be used for moderate to severe depression and commonly act to 
reduce the symptoms of depression after two weeks of use. They should show the targeted 
level of therapeutic action within less than two months and need to continue to be taken for at 
least six months (Lu and Roughead, 2012 & Shultz and Malone, 2013). A recent systematic 
review of randomised controlled trials for the treatment of depression in cancer patients 
suggests that pharmacological therapy alone using antidepressants or in combination with 
psychological therapy may be effective in the treatment of depression in cancer patients 
(Walker et al., 2014).  
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1.3.3 Management 
 
Regular follow-up of patients by health care professionals is important to ascertain the 
treatment of depression is working at satisfactory level. Health care professionals need to 
monitor the side-effects of the medicines, the psychological status of patients and adherence 
to treatment of patients by regular check-ups (Ellis et al., 2003; Ellis, 2004 & López-Torres et 
al., 2013). According to the National Institute for Health and Care Excellence (NICE) 
guidelines in the UK, a 2-4 week interval for follow-up should be considered in the first three 
months and then longer intervals of monitoring depending on the improvement of depression 
for adult patients (NICE, 2014). A pre-post cohort study showed that an additional telephone 
call by a pharmacist or nurse within 2 weeks of newly administering antidepressants 
improved the rate of scheduled follow-up and visit attendance by patients from 7% to 24% 
(Gallimore and Kushner, 2013). 
 
1.4 Prescription practices of antidepressants to cancer patients in Australia 
 
According to the National Health and Medical Research Council (NHMRC) clinical practice 
guidelines in Australia, use of antidepressants can improve the mental distress of cancer 
patients (NHMRC, 2003). However, the use of medications for the treatment of depression or 
anxiety may have decreased over time in Australia. The National Mental Health and 
Wellbeing survey showed that 1.8 million people in Australia suffered from a minimum of 
one 12-month affective mental disorder; whereas less than half of them took services for 
mental health treatment and the majority of them used services from a general practitioner 
(Australian Bureau of Statistics, 2008). Another National Health Survey in Australia (n= 
48,359) revealed that the prevalence of psychological distress decreased from 4.8% to 4.3% 
for cancer patients and 3.7% to 3.6% for non-cancer patients from 2001 to 2008. Similarly, 
the use of antidepressants by cancer patients for the treatment of psychological distress 
declined from 11.2% to 6.2% over the same 8 years (Atlantis et al., 2012). Given that 
depression rates are unlikely to have decreased, this could be due to underreporting or could 
indicate that cancer patients may not have sufficient access to adequate supportive care or 
that clinicians find it difficult to diagnose depression in cancer patients (somatic features of 
depression are very similar to cancer/treatment effects; difficulty to separate disorder from 
‘sadness’). Therefore it is a major issue to consider the prescription practices of 
antidepressants for cancer patients and their regular follow-up in Australia.       
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Various health professionals including physicians, oncologists, or psychiatrists may prescribe 
antidepressants to cancer patients. According to the Australian Institute of Health and 
Welfare, physicians prescribe 86% of antidepressants for the treatment of mental health in 
general, whereas psychiatrists prescribe only 8% and non-psychiatrists 6% of antidepressant 
medicines (AIHW, 2012). There is also variation in doses of antidepressants prescribed by 
providers to the depressive patients. Usually it has been identified that psychiatrists provide 
higher doses of antidepressants compared to general practitioners in Australia (McManus et 
al., 2003). However, it is not known which group of health care professionals prescribe most 
frequently to cancer patients comorbid with depression, what the dose of antidepressants is, 
how long patients take the medications, whether it has the desired benefit, whether the 
follow-up regimen is similar to what is recommended for mental health symptoms in people 
without cancer, and whether this follow-up is adequate. 
1.5. Studies conducted on prescription of antidepressants to cancer patients in Australia  
  
Only one population-based cohort study was identified in Australia conducted between 2005- 
2009 on cancer patients taking antidepressants (Pearson et al., 2015). Dispensing records was 
the main data source of information about antidepressants. This recent cohort study was 
conducted to assess the effect of a cancer diagnosis on prevalence and the timing of starting 
antidepressants. 17.2% (n= 995/5795) of cancer patients initiated antidepressants for the 
treatment of depression. The highest rate of treatment starting was from 12 weeks before to 
16 weeks after cancer diagnosis, while half of patients discontinued the antidepressants 
before 16 weeks of follow-up. Selective serotonin reuptake inhibitors (SSRIs) (47%, n= 
467/995) followed by tricyclic antidepressant (TCA) (33%, n= 328/995) was the commonly 
prescribed antidepressants and durations of treatment were shorter than recommended for 
depression (Pearson et al., 2015). This study did not analyse the prescription characteristics or 
practices by health care professionals, potential side effects or drug-drug interactions.  
Another cohort study of Australian military veterans (Lu and Roughead, 2012) was 
conducted on the persistent of antidepressant use by patients and reasons to cease the 
treatment. This study showed that cancer patients (n= 4,130/28,585) were at high risk of 
mental health impact due to higher rate of ceasing antidepressants before a six months course 
was completed compared to other chronic diseases patients such as those with diabetes, 
cardiovascular disease, or respiratory conditions. A recent multinational study which was 
identified in the literature search undertook research in eight different countries, including 
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Australia (n=70), and examined the use of antidepressants in advanced cancer patients 
(Janberidze et al., 2014). Overall, lack of follow-up after providing prescription of 
antidepressant to the cancer patients resulting in discontinuation of depression treatment was 
found from the previous studies.  However, no individual analysis on the prevalence of 
antidepressants in participating cancer patients from Australia was provided.   
Overall, there is a serious shortage of research on this topic in Australia. Particularly there is 
no significant study analysing the current prescribing practices for antidepressants in cancer 
patients in Australia.   
1.6 Knowledge gaps 
 
No literature review has been identified on the prescription practices of antidepressants to 
cancer patients. There is no information about what type and dose of antidepressants 
prescribed to the cancer patients, who prescribed these medicines, follow-up of 
antidepressants after providing to the patients. 
In the Australian context, there is a significant knowledge gap in this area. No cross-
sectional, prospective cohort, case-control or intervention study has been identified on the 
prescription practices of antidepressant to cancer patients. It is unknown which professional 
group (psychiatrist, medical oncologist, surgeon, pain specialist, general practitioner) most 
commonly prescribes antidepressants (type, dose, indication, change of medicines), whether 
patients are followed up about the benefit of the prescription, how long patients take these 
medicines, or why they are discontinued. 
A systematic review of existing literature in both Australia and worldwide is needed to 
determine the prescription practice of antidepressant to cancer patients in Australia before 
conducting further research. This review will help to identify the overall prevalence rate of 
antidepressants to cancer patients across the world and also to determine whether prescription 
prevalence varies depending on the study or patient characteristics. In addition, a systematic 
review of studies will also help to outline the suitable research methods and data collection 
procedures for future research in this area in Australia.           
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1.7 Thesis outlines 
 
To consider the lack of research and significant knowledge gaps on prescription of 
antidepressants to cancer patients, the current thesis, therefore had two main aims to be 
addressed in two studies: 
1.7.1 Study one: A systematic review and meta-analyses 
 
1. To describe the proportion of cancer patients who are prescribed antidepressants;  
2. To determine whether prescription prevalence varies depending on the study methodology 
or patient characteristics; 
3. To review the characteristics of antidepressants in each study according to study and data 
collection method. 
This study was designed to provide the following outcomes important for public health 
practice including- 
1. Overall pooled estimate of prescription prevalence of antidepressants to cancer patients 
from the published sources; 
2. Pooled estimate of prevalence of antidepressants to cancer patients according to study and 
patient characteristics;  
3. Type and dose of antidepressants prescribed by the health care provider;  
4. Trends of prescription of antidepressants over time; 
5. Follow-up of antidepressants after providing prescription. 
The literature was systematically searched according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) method using the keywords, 
‘antidepressants’, ‘prescription’, ‘psychotropic’ and ‘cancer’ in the databases of PubMed, 
Embase, Web of Science, Scopus and psychINFO. The comprehensive meta-analysis 
software (Version 3 by Borenstein, Biostat, Englewood, New Jersey, US, 2015) was used for 
the quantitative analysis of the obtained literature data. The article resulting from this review 
was accepted in the peer-reviewed journal ‘Psychooncology’.  
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1.7.2 Study two: A retrospective case-control study 
 
A retrospective, matched case-control study of antidepressants prescription in inpatients with 
or without cancer was conducted which aimed: 
1. To describe the sociodemographic and clinical characteristics of cancer inpatients and 
non-cancer inpatients prescribed antidepressants;  
2. To compare the antidepressants profile of these inpatients with cancer and an age and 
gender-matched sample without cancer;  
3. To determine the occurrence of adverse effects or potential drug-drug interactions of 
antidepressants with other medicines prescribed to cancer patients. 
This study was designed to address the following results important for public health practice 
including- 
1. Describe the characteristics of cancer and non-cancer patients who received antidepressant 
as inpatients, and their prescription profile including type, dose and prescriber; 
2. Differences in the characteristics of antidepressant prescriptions in cancer patients 
compared to non-cancer inpatients.  
This study was conducted by extracting prescription data from the clinical records and 
medicine records of 75 randomly selected inpatients within the first 12 months after diagnosis 
of cancer currently undergoing cancer or post-cancer treatment at Royal Brisbane Women’s 
Hospital, and 75 controls without cancer matched to the cancer patients by age and gender. 
This allowed ascertaining whether similar antidepressants were taken by cancer patients, the 
indication for this prescription, and the prescribers.  
 
1.8 Funding 
 
There was no funding involved in this project. 
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Chapter 2: A systematic review and meta-analysis  
 
 
A systematic review and meta-analysis was conducted at the starting point of thesis to 
determine the pooled estimate of prevalence of antidepressants to cancer patients and 
knowledge gaps of current studies. 
2.1 Background  
 
Globally cancer is one of the main contributors to the burden of disease and mortality (GBD 
2013 Mortality and Causes of Death Collaborators et al, 2015). Cancer patients commonly 
suffer from pre-existing or acquired co-morbidities including mental health problems (Hert et 
al., 2011). Mehnert et al. (2014) estimated that the four-week prevalence of mental health 
disorders in cancer patients is 31.8% (n=679/2,140) (Mehnert et al., 2014). In patients with 
advanced cancer, or those requiring palliative care, the prevalence rate of depression has been 
reported to be 15%-28% (Hotopf et al., 2002 and Walker et al., 2012).   
Antidepressants are widely prescribed for the pharmacological treatment of mental health 
disorders and some studies report that antidepressant prescription has increased over the last 
three decades (Helgason et al., 2004; Moore et al., 2009; Pratt et al., 2011 & Stephenson et 
al., 2012). According to the World Mental Health Survey (n=66,387) conducted in 24 
countries, the prevalence may vary widely between countries, and between cancer types, and 
many cancer patients may require yet not receive treatment for depression (Nakash et al, 
2014). Due to high symptom burden, patients themselves as well as health care professionals 
may fail to recognise depression, further increasing the treatment gap (Greenberg, 2004 & 
Gouveia et al., 2015). This is problematic because continuing untreated depression of cancer 
patients may cause increased hospitalisations, non-adherence to cancer treatments and shorter 
survival (Valente and Saunders, 1997, Pasquini and Biondi, 2007; Kissane, 2009 & Satin et 
al., 2009). 
While antidepressants may improve symptoms of depression, they also have side effects and 
can interact with cancer medications (Gøtzsche, 2014). For example, selective serotonin 
reuptake inhibitors (SSRIs) may reduce the efficacy of Tamoxifen, commonly prescribed in 
breast cancer treatment (Jaiyesimi et al., 1995; Onitilo et al., 2006 & Caraci et al., 2011). 
Furthermore, research has raised the possibility that some patients may receive 
antidepressants unnecessarily, while those on prescriptions may not be optimally followed 
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(Coyne et al., 2004; Janberidze et al., 2014 & Zhao et al., 2014). Regular follow-up of 
psychological status, adherence to treatment, potential drug-drug interactions or side-effects 
is clearly important (Ellis et al., 2003; Ellis, 2004; Trill, 2012 & López-Torres et al., 2013).  
One of the reasons for unwarranted prescription or lack of follow-up may be that many 
different medical specialities are involved in a cancer patients’ treatment.  Thus the 
coordination of treatment for cancer co-morbidities for which antidepressants may also be 
prescribed, including pain, fatigue, anorexia, hormonal dysregulation or insomnia, is 
complex.  
A systematic review and meta-analysis was therefore undertaken to describe the proportion of 
cancer patients who are prescribed antidepressants; whether prescription varies depending on 
the place of study or study methodology; cancer type and stage; patient age and sex; timing 
related to diagnosis or death; whether studies report on the type, dose, prescriber and follow-
up including monitoring of adverse side-effects or drug-drug interactions; duration of taking 
antidepressants and how many prematurely discontinue the treatment. 
2.2 Methods 
2.2.1 Search Strategy 
 
A systematic search of the published literature from 1979 (Earliest relevant article found) to 
February 2015 followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) method. We searched five databases (PubMed, Embase, Web of 
Science, Scopus, and psychINFO); the search strategy and time period covered by each of the 
databases is listed in Table 2.1.  
Table 2.1 Search strategy used in the different databases 
Name of 
Database 
Searched Terms 
Timeline showed 
during searching 
databases 
PubMed  cancer AND "Psychotropic Drugs"[Mesh] and prescription 
and "Antidepressive Agents"[Mesh] 
Aug 1979- Feb 2015 
Embase Antidepressant, prescription, cancer, Psychotropic Nov 1979- Jan 2015 
Web of 
Science 
Psychotropic and cancer and prescription and antidepressants Feb 1990-Oct 2014 
Scopus  Psychotropic and cancer and prescription and antidepressants Nov 1979-Dec 2014 
psychINFO psychotropic drug AND cancer AND prescription AND 
antidepressants 
Mar 2004- Apr 2013 
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The main Medical Subject Heading (MeSH) terms used were: ‘psychotropic’, 
‘antidepressants’, ‘prescription’, AND ‘cancer’. The bibliographies of relevant articles were 
also searched manually and relevant additional references included if they fulfilled the 
inclusion criteria (Figure 2.1). 
2.2.2 Inclusion and Exclusion Criteria 
 
Patient, outcome and study design criteria were: adult cancer patients or adult survivors of 
childhood cancer (studies of childhood cancer or adolescents younger than 18 years were 
excluded); article reports the proportion of cancer patients who were prescribed 
antidepressants to improve symptoms of depression. We excluded articles that researched 
antidepressants as a risk factor for cancer or cancer mortality; or where the antidepressants 
were used for management of symptoms other than depression. We included observational 
cohort, cross-sectional or case-control studies published in English. We excluded clinical 
trials of antidepressant efficacy, review articles or editorials. If several articles were based on 
the same dataset only the most detailed or most recent article was included to avoid repeated 
use of the same data. One study reported on three independent cross-sectional surveys at 
three different time points (Farriols et al., 2012), all three datasets were included separately in 
the meta-analysis. For relevant conference abstracts where no full article could be found, we 
contacted the authors to ask for the status of the publication. If the authors did not reply, we 
included data from the abstract only where it reported at least the proportion of cancer 
patients taking antidepressants.  
2.2.3 Data extraction  
 
The main characteristics of the studies used for sub-group analysis are presented in Table 2.2, 
including type, place and decade of study; source of prevalence data (i.e. prescription record; 
patient self-reporting questionnaire or interview; medical chart, or cancer registry; health care 
professionals reporting questionnaire; or dispensing record); patient age range and gender; 
cancer type and stage. Supplementary Tables 2.1 and 2.2 show sensitivity analyses of the 
main results when excluding studies with the highest or lowest prevalence, or grouping 
studies by full decades, respectively. Table 2.3 summarises in detail the reviewed studies in 
alphabetical order by first author’s surname, divided into cross-sectional, case-control (data 
extracted for cancer cases only) or cohort studies (last reported time-point used). Further data 
extracted included: duration of study; sample size; patient average/median age; sample 
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setting; who prescribed antidepressants; prevalence rate of antidepressants; type, and number 
of antidepressants (Table 2.3). 
2.2.4 Quality assessment and bias risk 
 
Quality and risk of bias (Table 2.3) were assessed by two scorers independently (MJ, SS). 
Quality included sample size; selection of sample according to study method; study design; 
presence of detail information of antidepressants. Bias included recruitment approach and 
non-response rate; completeness of medication data collection; and result reporting. Each 
scorer rated each study on a scale ranging from 1-4 for quality and 0-4 for bias (Mitchell et 
al., 2011) (Supplementary Table 2.3), average scores were used if disagreement was 1 point 
only; larger disagreements were resolved by discussion.     
2.2.5 Statistical Analysis  
 
Comprehensive Meta-Analysis (Version 3 by Borenstein, Biostat, Englewood, New Jersey, 
US, 2015) was used to calculate the prevalence rate and 95% CI overall, and by subgroups 
listed in Table 2.2.  
Heterogeneity was determined by Q and I
2
 values and >50% was considered as severe 
heterogeneity (Higgins et al., 2003). Publication bias was determined by using Begg’s funnel 
plot of standard error against logit event rate (Egger et al., 1997). Given that high 
heterogeneity was detected, we repeated the analyses after excluding studies which used data 
based on patient self-report, and studies with the highest and lowest prevalence rates from the 
overall result, and observed whether this made a >5% difference to the prevalence rate, 
however results remained largely unchanged. 
2.3 Results 
 
Overall 1,537 articles were found through the systematic (n=1,520) and manual (n=17) 
search. Figure 2.1 shows the PRISMA flow-diagram of screened and selected full-text 
articles.  
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Figure 2.1: PRISMA flow diagram of systematic review and meta-analysis 
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After excluding duplicates (n=812) and irrelevant studies (n=343), 382 articles remained. 
Irrelevant studies reported on biomedical or laboratory markers of depression, antidepressants 
prescribed to the general population, as risk factors for mortality of cancer patients, or use for 
pain, sleep disturbances or fatigue (Figure 2.1). Next 325 of the remaining 382 articles were 
excluded because on further review they did not fulfil the inclusion criteria, while 57 articles 
were read in full-text including three conference abstracts. Of these, 19 articles did not 
provide the required data for extraction. Therefore, 38 articles remained for meta-analysis. 
2.3.1 Overall prevalence  
 
Of 300,179 cancer patients included in the meta-analysis, 47,391 were prescribed 
antidepressants. Across all studies the pooled estimated prevalence of antidepressants 
prescribed was 15·6% (95% CI= 13.3-18.3), ranging widely from 0.5%-67% (Figure 2.2).  
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Figure 2.2: Weighted antidepressant prevalence rates 
2.3.2 Association of antidepressant prescribing with subgroup characteristics  
 
Prescribing prevalence was lower in cross-sectional (n=18, 12.5%, 95% CI= 10.1-15.4) 
compared to cohort studies (n=16, 19.6%, 95% CI= 16.2-23.5) (Table 2.2).  
 
  
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper Relative Relative 
rate limit limit weight weight
Ashbury et al., 2003 (n=1622) 0.161 0.144 0.180 2.69
Braun et al., 2015 (n=225) 0.227 0.177 0.286 2.54
Breitbart et al., 2000 (n=92) 0.402 0.307 0.505 2.42
Brelin et al., 2013 (n=17,753) 0.216 0.210 0.222 2.73
Brinkman et al., 2013 (n=8,277) 0.184 0.176 0.193 2.72
Chaturvedi et al., 1994 (n=146) 0.671 0.591 0.743 2.51
Chien et al., 2013 (n=87) 0.184 0.116 0.279 2.24
Coyne et al., 2004 (n=113) 0.239 0.169 0.326 2.39
Cullivan et al., 1998 (n=63) 0.254 0.162 0.375 2.20
de Bock et al., 2012 (n=2,172) 0.152 0.138 0.168 2.70
Derogatis et al., 1979 (n=1,579) 0.005 0.003 0.010 2.01
Desplenter et.al., 2012 (n=7,298) 0.098 0.091 0.105 2.72
Deyell et al., 2013 (n=2,389) 0.216 0.200 0.233 2.71
Dusetzina et al., 2013 (n=13,205) 0.240 0.233 0.247 2.73
Farriols et al., 2012 (n=241) 0.174 0.131 0.227 2.52
Farriols et al., 2012 (n=274) 0.281 0.231 0.337 2.59
Farriols et al., 2012 (n=325) 0.271 0.225 0.322 2.61
Findley et al., 2012 (n=865) 0.570 0.537 0.603 2.69
Fisch et al., 2014 (n=3,105) 0.193 0.179 0.207 2.71
Goldberg & Mor, 1985 (n=181) 0.028 0.012 0.065 1.72
Hung et al., 2013 (n=26,629) 0.196 0.191 0.201 2.73
Jaeger et al., 1985 (n=1,000) 0.098 0.081 0.118 2.64
Janberidze et al., 2014 (n=1,048) 0.135 0.115 0.157 2.67
Jones et al., 2015 (n=5,045) 0.184 0.173 0.195 2.72
Kelly et al., 2010 (n=24,430) 0.306 0.301 0.312 2.73
Khan et al., 2010 (n=26,213) 0.215 0.210 0.220 2.73
Lloyd-Williams et al., 1999 (n=1,046) 0.101 0.084 0.121 2.65
Lloyd-Williams et al., 2013 (n=629) 0.248 0.216 0.283 2.66
Ng et al, 2013 (n=111) 0.117 0.069 0.191 2.18
Ng et al, 2013 (n=113,887) 0.109 0.107 0.111 2.73
Ng et al, 2014 (n=3,345) 0.078 0.069 0.087 2.70
Pasquini et al., 2006 (n=165) 0.206 0.151 0.275 2.47
Pearson et al., 2015 (n=5,795) 0.172 0.162 0.182 2.72
Punekar et al., 2012 (n=4,287) 0.117 0.108 0.127 2.71
Stiefel et al., 1990 (n=200) 0.030 0.014 0.065 1.83
Suppli et al., 2011 (n=4,150) 0.246 0.233 0.259 2.72
Walker et al., 2014 (n=21,151) 0.017 0.016 0.019 2.71
Wilson et al., 2007 (n=381) 0.226 0.187 0.270 2.62
Yokoyama et al., 2012 (n=194) 0.010 0.003 0.040 1.11
Zhao et al., 2014 (n=460) 0.013 0.006 0.029 1.84
0.156 0.133 0.183
-0.80 -0.40 0.00 0.40 0.80
Combined 
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Table 2.2: Characteristics and sub-group analysis of study and sample 
Characteristics Number of 
studies (n=38) 
Prevalence (95%CI) Heterogeneity 
(I
2
) 
S
tu
d
y
 C
h
a
ra
ct
er
is
ti
cs
 
Study Method 
All studies 38 15.6% (13.3-18.3) 99.67 
Cross-sectional 18 12.5% (10.1-15.4) 99.47 
Cohort 16 19.6% (16.2-23.5) 99.12 
Case-control 4 14.5% (9.7-21.2) 99.02 
Place of the study 
North America 17 16.5% (12.9-20.9) 99·18 
Europe 14 17.1% (13.1-22)  99.76 
Asia 5 7.4% (4.3-12.5) 99.76 
Australia 1 17.2% (6.2-39.5)  
Multinational 1 13.5% (4.6-33.2)  
Decades according to year of publication 
1971-1980 1 0.5% (0.1-1.8)  
1981-1990 3 5.0% (2.5-9.7) 87.50 
1991-2000 4 32.0% (21.1-45.3) 98.65 
2001-2010 6 22.3% (15.5-30.9) 99.20 
≥2011 24 15.0% (12.4-18.1) 99.67 
Data collection method 
Prescription record 20 15.6% (12.5-19.3) 99.02 
Patient self-reporting questionnaire/ Interview  7 18.4% (12.4-26.5) 99.23 
Medical chart/ Cancer registry  6 15.3% (9.9-22.8) 99.58 
Health care professionals reporting 
questionnaire  
3 10.9% (5.7-19.7) 95.01 
Dispensing report 2 11.7% (5.6-22.8) 99.33 
S
a
m
p
le
 C
h
a
ra
ct
er
is
ti
cs
 
Average/Median age 
25-34 1 21.6% (7.3-48.9)  
35-44 1 19.6% (6.6-45.8)  
45-54 3 8.1% (3.8-16.5) 99.27 
55-64 12 13.7% (9.9-18.7) 99.47 
65-74 11 16.5% (11.9-22.5) 99.77 
75-84 2 17.8% (8.2-34.3) 63.90 
Not specified 8 16.7% (11-24.4) 99.19 
Gender 
Females only 6 22.6% (16-31) 99.46 
Both 29 15.1% (12.7-17.9) 99.59 
Not specified 3 5.7% (2.7-11.6) 92.52 
Cancer type 
Single type
1
 7 22.1% (16-29.7) 99.35 
2-4 types
2
 4 18.8% (12.1-27.9) 94.15 
Any 27 13.5% (11.2-16.2) 99.52 
Cancer stage 
Cured or remission 1 22.7% (8-49.8)  
Any stage 11 12.6% (9-17.2) 99.66 
Advanced/ Terminal stage 11 16.1% (12.3-20.8) 95.76 
Not reported 15 15.8% (12-20.5) 99.76 
1
Single type included breast (n=6; 22·6%; 95% CI= 16.0-30.9) or pancreatic cancer (n=1; 18.4%; 95% CI= 6.6-
41.8). 
2
2-4 types included breast, colon, lung, prostate cancer 
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Studies conducted in Asia (n=5) showed lower prevalence rates (7.4%, 95% CI= 4.3-12.5) 
compared to studies from other continents (Table 2.2). Two studies in Asia identified only a 1 
to 1.3% prevalence rate (Yokoyama et al., 2012 & Zhao et al., 2014). Zhao et al. (2014) 
reported that while the one-month prevalence of depressive disorder was 25% (n=119/460), 
only six patients were prescribed antidepressants (Zhao et al., 2014).   
Prevalence rates between studies differed depending on the source of data, with highest rates 
from patient self-reporting questionnaire or interviews (18.4%, 95% CI= 12.4-26.5) and 
lowest from physician-reported questionnaires (10.9%, 95% CI= 5.7-19.7), or dispensing 
reports (11.7%, 95% CI= 5.6-22.8) (Table 2.2).  
Few patient characteristics were associated with prescription practices, and no clear pattern 
emerged with regards to cancer stage; however, compared to other cancer patients, women 
and those with breast cancer were more commonly prescribed antidepressants (Table 2.2). 
There was a u-shaped association between age group and prescribing prevalence.  
Prescription details are summarised in Table 2.3, twenty one studies presented the type or 
name of the antidepressants. Among these studies, SSRIs were most commonly prescribed. 
Nine articles detailed the full range of antidepressants (Chaturvedi et al., 1994; Lloyd-
Williams et al., 1999; Pasquini et al., 2006; Kelly et al., 2010; de Bock et al., 2012; Brelin et 
al., 2013; Lloyd-Williams et al., 2013 & Pearson et al., 2013). In some instances, cancer 
patients received more than one type of antidepressant (Chaturvedi et al., 1994; Kelly et al., 
2010 & Deyell et al., 2013) or the type of antidepressant changed over the course of cancer 
treatment (Pearson et al., 2013). 
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Table 2.3: Studies reporting prevalence of antidepressant prescriptions to cancer patients 
Study Quality Bias 
Risk 
Place of 
study 
Duration 
of study 
Sample 
size  
Average/ 
Median 
age 
Gender Cancer Type  
 
Cancer 
Stage  
Sample 
setting 
Who prescribed 
antidepressant 
Prevalence of 
Antidepressa
nt 
Types & number 
of antidepressant 
taking by cancer 
patients 
Cross sectional studies 
Antidepressants prescription data reported from prescription record 
Ashbury et 
al., 200329 
3 2.5 USA 
 
Nov 1999-
Nov 2001 
1622 Average 
64.7 
M(n=435/1622) 
F(n=1187/1622) 
Breast(n=850/1622), 
Colon(n=299/1622), 
Lung(n=473/1622) 
Any stage 
 
Community 
Oncology 
Practice 
Oncologist 16% 
(n=261/ 
1,622) 
NR 
Coyne et 
al., 200421 
3.5 3 USA NR 113 NR Only F(n=113) Breast (n=113) 
 
Stage 1 
(n=24/113) 
Stage 2a 
(n=31/113) 
Stage 2b 
(n=27/113) 
Stage 3a 
(n=11/113) 
Stage 3b 
(n=9/113) 
Stage 4 
(n=11/113) 
Waiting 
Room sample 
NR 24%(n=27/113) NR 
Cullivan et 
al., 199830 
2 3 Ireland 1997(July-
Dec) 
63 NR M(n=15/63) 
F(n=48/63) 
Any type 
 
Any stage Inpatient Oncologist, 
General 
Practitioner, 
Psychiatrist 
26%(n=16/63) 
 
Type:  
SSRI- 
Nefazodone & other 
Derogatis 
et al., 
197931 
2.5 2.5 USA 1977(April- 
Sep) 
1,579 Average 
age 54 
M(n=631/1,579) 
F(n=948/1,579) 
Any type 
 
NR Inpatient, 
Outpatient 
NR 0.5%(n=8/1,579) 
 
Type:  
TCA- 
Amitriptyline,  
Imipramine 
Farriols et 
al., 201228 
2.5 2.5 Spain 2002 241 Average 
age 69.7 
 
M(n=161/241) 
F(n=80/241) 
Any type 
 
Advanced 
cancer 
Palliative care Psychiatrist 17%(n=42/241) 
  
Type:  
Paroxetine(n=23/42)  
Amitriptyline 
(n=8/42),  
Fluoxetine(n=6/42),  
Citalopram(n=4/42), 
Trazodone(n=1/42) 
Spain 2006 274 Average 
age 71.6 
M(n=170/274) 
F(n=104/274) 
28%(n=77/274) 
 
Type:  
Mirtazapine 
(n=35/77),  
Citalopram 
(n=33/77),  
Paroxetine 
(n=11/77),  
Venlafaxine 
(n=7/77),  
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Amitriptyline 
(n=3/77),  
Fluoxetine(n=3/77),  
Duloxetine(n=1/77),  
Others(n=2/77) 
Spain 2009 325 Average 
age 72.2 
M(n=196/325) 
F(n=129/325) 
27%(n=88/325) Type: Mirtazapine 
(n=30/88),  
Escitalopram 
(n=23/88) 
Citalopram 
(n=15/88),  
Paroxetine(n=8/88),  
Amitriptyline 
(n=7/88),  
Trazodone(n=7/88), 
Duloxetine(n=6/88),  
Venlafaxine 
(n=5/77),  
Fluoxetine(n=1/88),  
Others(n=5/88) 
Jaeger et 
al., 198532 
3 1.5 USA Jan 1981- 
Feb 1982 
1000 Average 
age 68.2 
M(n=550/1000)
F(n=450/1000) 
Any type 
 
NR Inpatient Physician, 
Psychiatrist 
10%(n=98/1000) 
 
Type: Amitriptyline,  
Imipramine 
Lloyd-
Williams et 
al., 199933 
2.5 1.5 UK 1995(Jan-
Dec) 
1046 Average 
age 61.3  
NR Any type 
 
Terminal 
cancer 
Palliative care Psychiatrist 14.6% 
(n=153/1046) 
 
Type: TCA-24.5%, 
SSRI-71.8%, MOA-
1.9% 
Dothiepin-
25mg/day, 
Fluoxetine,  
Paroxetine,  
Sertraline,  
Flupenthixol,  
Phenelzine 
Punekar et 
al., 201234 
3 1.5 USA 2001-2006 4287 NR M(n=1691/4287) 
F(n=2596/4287) 
Any type 
 
NR Cancer 
survivor 
NR 11.7% 
(n=503/4287) 
NR 
Antidepressants prescription data reported from medical record/ chart & cancer registry 
Breitbart et 
al., 200035 
3 2 USA, 
 
Jun 1998- 
Jan 1999 
92 Average 
age 65.9 
M(n=37/92) 
F(n=55/92) 
Any type 
 
Terminal 
cancer 
Inpatient NR 40%(n=37/92) NR 
Chien et 
al., 201336 
1.5 2 Taiwan 2010 87 NR NR Pancreatic cancer 
 
Advanced 
cancer 
NR NR 18·4%(n=16/87) NR 
Chaturvedi 
et al., 
199437 
2.5 2 UK 
 
NR 146 Average 
age 49 
(19-83) 
M(n=46/146) 
F(n=100/146) 
Any type 
 
NR Inpatient, 
Outpatient 
Psychiatrist 67%(n=98/146) 
 
Type: 
Dothiepin(n=74/110
)-25-225mg,  
Mianserin(n=13/110
)-10-30mg, 
Amitriptyline(n=9/1
20 
 
10)-50-175mg,  
Clomipramine(n=5/
110)-50-150mg 
Other-(n=9/110) 
Number:  
One (n=86/98),  
Two (n=12/98), 
Total number of 
prescription, n=110 
Walker et 
al., 201438 
4 1.5 UK 2008-2011 21151 Average 
age 64.4 
M(n=6039/21151) 
F(n=15112/21151) 
Breast 
(n=8461/21,151),  
Lung 
(n=4316/21,151), 
Colorectal 
(n=3355/21,151), 
Genitourinary 
(n=2009/21,151), 
Gynaecological 
(n=3010/21,151) 
 
NR Outpatient Psychiatrist 1.75% 
(n=370/21151) 
Type:  
Amitriptyline, 
Citalopram, 
Clomipramine, 
Dosulepin,  
Doxepin,  
Duloxetine, 
Escitalopram, 
Fluoxetine,  
Flupentixol, 
Fluvoxamine, 
Imipramine, 
Lofepramine, 
Mirtazapine, 
Nortriptyline, 
Paroxetine, 
Phenelzine, 
Reboxetine, 
Sertraline,  
Trazodone, 
Trimipramine, 
Venlafaxine. 
Zhao et al., 
201423 
2.5 2.5 China 2013(Marc
h-Sep) 
460 Average 
age 59.4 
M(n=226/460) 
F(n=234/460) 
Any type 
 
Any stage Inpatient Psychiatrist, 
Oncologist 
1.3% (n=6/460) NR 
Antidepressants prescription data reported from health care professionals reporting questionnaire 
Janberidze 
et al., 
201422 
3.5 1.5 Norway 
Austria 
Italy 
Switzerland 
England 
Australia 
Canada 
Germany 
Oct 2008- 
Dec 2009 
1048 Average 
age 62·5 
M(n=540/1048) 
F(n= 508/1048) 
Any type 
 
Advanced 
cancer 
Inpatient, 
Outpatient 
NR 14% 
(n=141/1048) 
NR 
Stiefel et 
al., 199039 
3 1.5 USA Dec 1987 200 Average 
age 52 
NR Any type 
 
NR Inpatient Physician 3%(n=6/200) 
 
Type: Amitriptyline, 
Desipramine, 
Maprotiline 
Antidepressants prescription data reported from self-reporting questionnaire/ interview 
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Findley et 
al., 201240 
3.5 2.5 USA 2000-2005 865 NR M(n=593/865) 
F(n= 272/865) 
Any type 
 
NR Medicare 
Current 
Beneficiary 
NR 57%(n=493/865) 
 
Type: MAO 
SSRI 
SNRI 
TCA 
 
Goldberg 
& Mor, 
198541 
2.5 2.5 USA NR 181 NR M(n= 96/181) 
F(n= 85/181) 
Any type 
 
Terminal 
cancer 
Hospice 
sample 
NR 2.76%(n=5/181) 
 
SSRI/SNRIs  
Doxepine,  
Amoxapine,  
Amitriptyline,  
Imipramine 
Yokoyama 
et al., 
201242 
1.5 3.5 Japan 2010(June-
Dec) 
194 NR NR Hematological, 
Esophageal, 
Gastric, 
Pancreatic, 
Colon, 
Lung, 
Breast, 
Ovarian, 
Uterine, 
Skin 
NR Outpatient NR 1%(n=2/194) NR 
Case-control studies 
Antidepressants prescription data reported from prescription record 
Desplenter 
et.al., 
201243 
3 1.5 UK 2005-2010 7298 Average 
age 67.8 
M(n=3595/7298) 
F(n=3703/7298) 
Breast(n=1547/7298) 
Colorectal 
(n=1270/7298), 
Lung(n=1299/7298), 
Prostate 
(n=1058/7298), 
Upper GI 
(n=540/7298), 
Melanoma 
(n=402/7298), 
Gynaecological 
(n=445/7298) 
Urological 
(n=737/7298) 
NR General 
Practice 
General 
Practitioner 
9.8% 
(n=713/7298) 
 
Type: TCA,  
Other 
Jones et 
al., 201544 
2.5 1.5 USA 2005-2011 5045 Average 
age 77 
M(n=2686/5045) 
F (n=2359/5045) 
Prostate  
(n= 2686/5045), 
Breast 
(n=2359/5045) 
 
NR NR NR 18.4%(n=928/ 
5045) 
Type: SSRI, SNRI, 
TCA, MAO 
 
Ng et al, 
2013b45 
3 1 Netherland Jan 2006- 
Dec 2008 
113887 Average 
age 60.45 
M(n=42594/ 
113887) 
F(n=71293/ 
113887) 
Any type 
 
Any stage Health 
insurance 
company 
NR 10·9% 
(n=12414/113887) 
NR 
Antidepressants prescription data reported from self-reporting questionnaire/ interview 
Braun et 
al., 201546 
3 2.5 USA NR 225 Average 
age 59.5 
M(n= 80/225) 
F(n= 135/225) 
Any type 
 
Cure/ 
remission 
stage 
National 
Comorbidity 
Study 
Psychiatrist 
Physician 
22.6% 
(n=51/225) 
NR 
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Replication 
Cohort studies 
Antidepressants prescription data reported from prescription record 
Brelin et 
al., 201347 
3.5 3.5 Norway Jan 2005- 
Dec 2006 
17753 Average 
age 71.9 
M(n=9617/17753) 
F(n=8136/17753) 
Any type 
 
Terminal 
stage 
Norwegian 
Prescription 
Database 
General 
Practitioner 
Physicians with 
no registered 
specialty 
Internists 
surgeons 
Oncologist 
Psychiatrist 
22% 
(n=3836/17753) 
 
Type: TCA-
21%(n=816/3836), 
SSRI-
56%(n=2131/3836), 
TeCA-
19%(n=717/3836), 
MAOI-
<1%(n=7/3836), 
SNRIs 4% 
(n=145/3836), 
Other-
<1%(n=20/3836) 
Citalopram 
Escitalopram 
Mianserin 
Mirtazapine 
de Bock et 
al., 201248 
3 3 Netherland 1994-2006 2172 Average 
age 62 
Only F(n=2172) Breast(n=2172) 
 
NR Prescription 
data 
General 
practitioner 
15% 
(n=331/2172) 
 
Type:  
Amitriptyline 
(n=144/331) 
Paroxetine 
(n=66/331) 
Venlafaxine 
(n= 38/331) 
Citalopram 
(n= 25/331) 
Mirtazapine 
(n= 19/331) 
Others(n=39/331) 
Deyell et 
al., 201349 
3 3 Canada Jan 2001- 
Dec 2004 
2389 Average 
age 28.3 
M 
(n=1225/2389), 
F 
(n=1164/2389) 
Any type 
 
NR BC Cancer 
Registry 
NR 21.6%(n=515/2
389) 
Type: MAO, SSRI 
Serotonin 
modulators 
TCA, Other 
Number: One 
(n=346), 
≥Two(n=169) 
Dusetzina 
et al., 
201350 
2.5 2.5 USA July 2004- 
Dec 2009 
13205 Average 
age 60.5 
Only F 
(n= 13205) 
Breast(n=13205) 
 
NR Inpatient, 
Outpatient 
Oncologist 
Primary carer 
Oncologist 
Primary carer 
24% 
(n=3169/13205) 
NR 
Hung et 
al., 201351 
2.5 2.5 Taiwan Jan 2000-
Dec 2005 
26629 Median 
age 44 
Only 
F(n=26629) 
Breast(n=26629) 
 
Early & 
advanced 
stage 
Inpatient, 
Outpatient, 
Emergency 
NR 19.6% 
(n=5223/26629) 
NR 
Kelly et 
al., 201052 
3.5 0.5 Canada 1993-2005 24430 Median 
age 74 
NR Breast(n=24430) 
 
NR Cancer 
Registry 
NR 31% 
(n=7483/24430) 
 
Type: SSRI  
(56%,n=4190/7483), 
SNRI 
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Paroxetine(n=1938), 
Sertraline(n=1872), 
Citalopram(n=1762) 
Venlafaxine 
(n=1205),  
Fluoxetine-(n=994) 
Fluvoxamine-
(n=772) 
Number: 
One (n=3974/7483), 
Two (n=2582/7483), 
Three (n=927/7483) 
Khan et al., 
201053 
2.5 2.5 UK 2003-2006 26213 Average 
age 72.36 
M 
(n=6805/26213)  
F(n= 
19437/26213) 
Breast (n=16773), 
Colorectal 
(n=4982), Prostate 
(n=4458) 
Any stage General 
Practice 
Research 
Database 
General 
Practitioner 
21.5% 
(n=5638/26213) 
NR 
Ng et al, 
2013-a54 
2.5 1.5 Netherland Jan 2005-
Dec 2009 
111 Average 
age 70.77 
M(n= 59/111) 
F(n= 52/111) 
Any type 
 
Terminally 
stage 
General 
Practitioner 
Research 
Network 
General 
Practitioner 
11.7% 
(n=13/111) 
NR 
Ng et al, 
201455 
2.5 2.5 Malaysia Jan 2008- 
Dec 2012 
3345 Average 
age 57 
M(n=1036/3345)  
F(n=2309/3345) 
Any type 
 
NR Inpatient NR 7.8% 
(n=260/3345) 
NR 
Pearson et 
al., 201356 
3.5 0.5 Australia Jan 2005-
Dec 2009 
5795 Median 
age 82 
M(n=3660/5795)  
F(n=2135/5795) 
Any type 
 
NR Veterans’ 
population 
General 
Practitioner 
17.2% 
(n=995/5795) 
Type: SSRI-
46.9%(n=469/995), 
TCA- 
32.9%(n=327/995) 
Other-
20.2%(n=201/995) 
Suppli et 
al., 201157 
3 1.5 Denmark 1998-2006 4150 NR F(n=4150) Breast(n=4150) 
 
NR Breast Cancer 
Cooperative 
Group 
NR 25% 
(n= 1020/4150) 
NR 
Antidepressants prescription data reported from medical record/ chart & cancer registry 
Wilson et 
al., 200758 
2.5 1.5 Canada NR 381 Average 
age 67.2 
NR Any type 
 
Terminal 
stage 
Inpatient, 
Palliative care 
units, 
Outpatient, 
Home care 
NR 22.5% 
(n=86/381) 
 
Type: SSRI, TCA 
Antidepressants prescription data reported from health care professionals reporting questionnaire 
Fisch et al., 
201459 
2.5 1.5 USA March 
2006- May 
2008 
3106 Average 
age 61 
M(n= 
936/3106) 
 F(n= 
2170/3106) 
Breast(n=1544), 
Colon(n=717), 
Lung(n=320), 
Prostate(n=525) 
 
Any stage Outpatient NR 19.3% 
(n=599/3106) 
 
Type: 
SSRI/SNRIs,TCA, 
Antidepressants prescription data reported from self-reporting questionnaire/ interview 
Brinkman 
et al., 
3 2 USA 1994-2007 8277 NR NR Any type 
 
NR Childhood 
Cancer 
Physician 19.1% NR 
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201360 Survivor (n= 1527/8277) 
Lloyd-
Williams et 
al., 201361 
3 2 UK Nov 2007-
Aug 2009 
629 Average 
age 66 
M(n=207/629) 
F(n=422/629) 
Any type 
 
Advanced 
cancer 
Hospice 
day care units 
NR 25% 
(n=156/629) 
 
Type: 
SSRI-70%,  
NSSA-30% 
Number: 
Recommended 
therapeutic dose 
ranges 
Pasquini et 
al., 200662 
2 2.5 Italy Oct 2003- 
July 2004 
165 Average 
age 58.2 
M(n= 73/165) 
F(n= 92/165) 
Any type 
 
Any stage Hospital 
Patient 
Psychiatrist 20.6% 
(n=34/165) 
 
Type: 
Mirtazapine 
(n=15/34)-15mg,  
Citalopram 
(n=13/34)-10mg,  
Escitalopram 
(n=4/34)-5mg,  
Fluvoxamine & 
Paroxetine-(n=2/34) 
1ranged from high quality (4) to low quality (1). 2ranged from high risk (4) to no risk (0). SSRI- Selective serotonin reuptake inhibitor, TCA- Tricyclic antidepressant, MAO- Monoamine oxidase, SNRI- Serotonin–
norepinephrine reuptake inhibitor, NSSA- Noradrenaline-serotonin specific antidepressant, NR- Not Reported 
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According to the World Psychiatric Association, the initial dose of an antidepressant should 
be about half of the expected therapeutic dose, with increased dosing depending on the 
changes in the depressive status of the patient (Riba and Grassi, 2008). Only Chaturvedi et al. 
(1994) and Pasquini et al. (2006) reported the dose of antidepressants, with Chaturvedi et al. 
(1994) highlighting the wide range of dose prescribed. Lloyd-Williams et al., (2013) 
indicated that patients were prescribed antidepressants according to recommended therapeutic 
dose ranges, but did not report the specific dose for each patient.  
No clear pattern emerged when studies were grouped by time since diagnosis or time to 
death, with studies that focussed on the same time window reporting high or low rates, 
indicating that other variables such as type of study or type of data collection method may be 
more important to explain differences between studies. Only two studies focussed on 
antidepressant initiation before cancer diagnosis or treatment (Kelly et al., 2010 & Pearson et 
al., 2013). Among breast cancer patients, 44% of antidepressants (n=3,311/7,483) were 
prescribed concomitantly with Tamoxifen therapy, with the remaining patients prescribed 
antidepressants six months before starting breast cancer treatment (Kelly et al., 2010 ). From 
dispensing records Pearson et al. (2015) identified that 34.9% of patients (n= 347/995) were 
prescribed antidepressants three to four months before the cancer diagnosis. Early symptoms 
of cancer or prevention of depression when facing the diagnosis may explain this increase in 
prescriptions (Pearson et al., 2015). Another noticeable peak in antidepressant use was 
identified by three studies during the last three months of life (Ng et al., 2013b; Brelin et al. 
2013 & Lloyd-Williams et al., 1999). 
To achieve therapeutic action, antidepressants should be used for no less than eight weeks 
and continued for at least 24-36 weeks (Riba and Grassi, 2008; Lu and Roughead, 2012 & 
Shultz and Malone, 2013). In contrast, Lloyd-Williams and colleagues (2013) noted that the 
median duration of use was only 9.5 weeks. Pearson et al. (2015) identified a median 
duration of antidepressant use of 16 weeks with breaks and 11 weeks without breaks from the 
dispensed prescriptions. Furthermore, half of the patients (50.5%, n=502/995) discontinued 
treatment during the follow-up period (Pearson et al., 2013). However, Kelly et al. (2010) 
identified a long duration of use in breast cancer patients, with a median of 74.8 weeks.   
Only two studies detailed the proportion of prescriptions by different medical specialties. In 
Cullivan et al. (1998) study (n= 16/63), oncologists were the most common prescriber (46%). 
Brelin et al. (2013) nationwide Norwegian research (n= 3,836/17,753) identified general 
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practitioners as the highest antidepressant prescribers (50%), with a very small proportion of 
prescriptions by oncologists (3.7%) or psychiatrists (0.8%) (Table 2.3).   
2.3.3 Additional Analyses 
 
Overall, the studies showed significant heterogeneity (Q= 11464.11, I2= 99·65%). The funnel 
plot showed asymmetry (Figure 3.1), indicating likely publication bias. Sensitivity analyses 
(Supplementary Table 2.1) eliminated studies with the highest and lowest prevalence of 
antidepressant prescriptions one by one, and grouped studies differently by decades 
(Supplementary Table 2.2), trends of prescription of antidepressants over time 
(Supplementary Table 2.4) and study period (Supplementary Table 2.5). None of these 
substantially changed the results or conclusions.  
 
 
Figure 2.3: Begg’s funnel plot of standard error against logit event rate. 
 
2.4 Conclusions 
 
According to the pooled estimate from all included studies, 15.6% of cancer survivors were 
prescribed antidepressants, which is higher compared to previous reports from the general 
population in the USA (11%) (Pratt et al., 2011). A large proportion of studies in our review 
(n=14/38, 37%) were conducted in the USA, and compared to these studies, antidepressant 
prescriptions were considerably less common in studies conducted in Asia (7.3%). Four case-
control studies reported that a higher proportion of cancer patients were prescribed 
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antidepressants than non-cancer patients, if the data were collected from prescription or 
health records (Desplenter et. al., 2012; Ng et al, 2013b; Braun et al., 2015 & Jones et al., 
2015). However, several studies identified a considerable treatment gap and potential under-
use of antidepressants. For example, the rate of antidepressants users was much lower than 
the rate of cancer patients identified with depressive disorder using validated diagnostic 
depression scales (Cullivan et al., 1998; Desplenter et.al., 2012; Yokoyama et al., 2012; Fisch 
et al., 2014; Walker et al., 2014; Yokoyama et al., 2012 & Zhao et al., 2014).  Even some 
cancer patients diagnosed with major depression were not receiving treatment for depression 
or support by qualified mental health professionals (Yokoyama et al., 2012 & Zhao et al., 
2014). However, Mitchell et al. (2011) reported a pooled prevalence rate of depression of 
16.5% (95% CI= 13.1-20.3) in patients from palliative care and advanced cancer care settings 
and if these patients were prescribed antidepressants this would reflect closely the rate of 
prescribing identified in this review. 
Marked variation in prevalence rates were observed in this review including by study sample 
size, setting, data collection methods and time since diagnosis reflected in the sub-group 
results (Table 2.2, Table 2.3 and Figure 2.2). The sample size of the studies ranged from 63 to 
113,887. Studies collected the data from different settings nationally (n=37) and multi-
nationally (n=1) with different gender, population, community, and hospital inpatients or 
outpatients service characteristics. There was also a large difference in the duration of time 
for which prescription data was collected from a minimum of six months (Derogatis et al., 
1979; Cullivan et al., 1998; Yokoyama et al., 2012 & Zhao et al., 2014) to a maximum of 12 
years (Kelly et al., 2010 & de Bock et al., 2012). Several differences in prevalence rate of 
greater than 5% were observed in the sub-group analysis with place of study, decade of study 
and data sources all showing considerable variability (Table 2.2).  
Pooled estimates of prevalence may not represent individual countries. To minimise this 
problem, we undertook sub-group analysis by continent (Table 2.2), which showed 
considerable discrepancy in prescribing especially for Asia with 4 out of 5 studies reporting 
lower prevalence rates than in studies (Yokoyama et al., 2012; Chien et al., 2013; Ng et al, 
2014 & Zhao et al., 2014). Only Hung et al. (2013) identified a higher prevalence rate of 
antidepressant use and diagnosed mood disorder (19.6%, n=5,223/26,629) determined by 
International Classification of Diseases, 9th revision (ICD-9), in a nationwide population-
based breast cancer study in Taiwan. Zhao et al. (2014) discussed potential reasons for low 
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rates of prescription of antidepressants in China. Unavailability of mental health professionals 
or psycho-oncology services in general hospitals was stated as a driving reason for both the 
high prevalence and low recognition of depression (any depressive disorder, 25.9%, 
n=119/460; recognised depression, 3.4%, n=4/119; prescribed antidepressants, 2.5%, 
n=3/119). Other problems included difficulties in diagnosis of depression, and inadequate 
training in recognising psychiatric symptoms (Zhao et al., 2014). Failure to diagnose 
depression and attention focussed on cancer treatments were also discussed as reasons for 
low prevalence of antidepressant use in Malaysia (7.8%, n=260/3,345) (Ng et al., 2014). 
Recognition of depression is challenging for non-mental health professionals (Couper et al., 
2012). Zhong et al. (2010) conducted a study on recognition of depression in hospital 
inpatients in China and found that while 16.2% (n=83/513) and 9.4% (n=48/513) of patients 
had depressive and major depressive disorder according to DSM-IV, respectively, none of 
these patients had been recognised by health care professionals or received treatment. Low 
recognition of depression by prescribers has also been identified as a common problem 
among the general population in eight Asian countries (Chen et al, 2013) and European 
countries (Sharpe et al., 2004). Biological differences among Asians in their P450 cytochome 
enzymes in the liver, utilised in metabolism of antidepressants, may also explain lower 
utilisation rates in this ethnic group (van der Weide and Hinrichs, 2006). 
Health care professional-reported data resulted in lower prevalence rates (10.9%) compared 
to other data collection methods (Fisch et al., 2014 & Janberidze et al., 2014).  This may 
either reflect a more precise estimate or lack of awareness among the health care 
professionals that the patient is taking antidepressants from another prescriber. Pérez-Stable 
et al. (1990) conducted a study on physician-recognised depression (defined by a prescription 
of antidepressants) compared with Diagnostic Interview Schedule (DIS). Among 70 patients 
diagnosed with depression using the DIS, only 25 patients were identified by physicians. Two 
decades later Punekar et al. (2012) showed that use of antidepressants prescriptions had 
increased greatly in cancer patients, but underdiagnoses and underuse of effective treatments 
are still persisting in many countries around the world as discussed above. 
Most of the studies (n=31) included patients diagnosed with multiple types of cancer, and 
considered which patients were more likely to be prescribed antidepressants depending on the 
origin of cancer, physical or socio-economic status (Table 2.2). Female cancer survivors 
diagnosed with breast cancer were more likely to be prescribed antidepressants compared to 
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other cancer survivors, for example those with colon, lung or prostate cancer (Ashbury et al., 
2003; Khan et al., 2010 & Zhao et al., 2014). Women were three times more likely to have an 
antidepressant prescription compared to men (Male; 3%-8.5% vs Female; 9.2%-22.8%) of the 
same age range in one study (Pratt et al., 2011), consistent with higher rates of depression in 
women compared to men (Silva et al., 2014).  Hormonal, psychosocial or disease factors are 
discussed as the possible reasons for high prevalence of antidepressant prescription (Kelly et 
al., 2010 & Suppli et al., 2011). Most of the studies indicated the reason for prescription of 
antidepressant was depression. Only few studies reported that the medication was prescribed 
for pain, anxiety (Coyne et al., 2004 & Brinkman et al., 2013), hot flushes, nerve pain, as 
psychostimulants (Fisch et al., 2015), for sleep (Jaeger et al., 1985), or somatization 
(Brinkman et al., 2013). 
Few of the reviewed studies (n=6) reported details on the prescriber characteristics, and few 
(n=8) focussed on the exact details of the prescription. In part this may be associated with the 
data extraction methods, which also varied widely across the studies, and had a clear 
influence on the prevalence rate (Table 2.2). Prospective studies in oncology which assess in 
detail the reasons for prescribing of antidepressants from progress notes or indication present 
in the prescription record of hospital. The health care providers involved are urgently needed, 
as well as better data about the follow-up regimen used to assess the response to treatment, 
and potential side effects. During the quality assessment we identified that few studies 
reported the characteristics of the underlying population, therefore selection bias is a risk of 
most included studies, which could be addressed in future prospective studies.  
Strengths of this study include its systematic search strategy, review of cross-sectional, cohort 
and case-control studies across five decades. It found a number of characteristics associated 
with prescribing, including continent, data source, patient gender, age and cancer type. It 
identified considerable heterogeneity and asymmetry in results, clearly highlighting that 
further high quality studies are required. Future studies may consider using more than one 
data source (for example extraction from clinical files complemented by patient self-report) 
and also report details that allow with certainty distinguishing whether the antidepressant 
medication was used to treat mental or physical symptoms. Few studies reported on who 
prescribed the medication. Those that did seem to indicate that prescriptions for 
antidepressants are rarely provided by mental health professionals, much more commonly by 
primary health care providers or non-psychiatrist physicians and it would be interesting to 
investigate if this makes a difference with regards to treatment adherence and follow-up. 
30 
 
Interactions between antidepressants and cancer treatment drugs are an increasing concern, 
and high quality data would allow to better discern which patients may be at risk of receiving 
suboptimal combinations of mental health and cancer fighting drugs. 
2.5 Summary 
 
This systematic literature review was undertaken as a part of Masters course and it was found 
that only one retrospective cohort study was conducted on this area in Australia. Different 
approaches were taken for the next research in this Masters research to assess the prescription 
practices of antidepressants to cancer patients in Australia. The potential research methods 
that could be employed and were considered included prospective cohort study, case-control 
study, or intervention study on different types of cancer patients or the major types of cancer 
such as lung, prostate, breast or blood cancer.  
Additional factors that had to be taken into account in finalising the decision for the study 
design were optimal research method given the limited time frame available until completion 
of the course, data collection from newly recruited sample or exiting medical records, number 
of ethics application required to apply and other clearances, design and content of research, 
sample size, data analysis, cost of research and so on. After considering all these factors 
involved in the research, data collection from the existing medical records of a tertiary 
hospital that has a collaborative agreement with QUT was chosen the best way forward for 
this research in the limited time frame of Master course. The matched case-control study 
design showed the following merits - 
 Allowed greater precision in estimates at comparatively small sample size  
 Allowed to select the sample from a large comprehensive database system without direct 
patient involvement  
 Conducted within the time frame of Master course 
 Reasonably  time-consuming ethics applications and other clearances 
 No funding required  
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Chapter 3: A retrospective case-control study  
 
After the systematic literature review and meta-analysis was completed and all relevant 
approvals were obtained, data collection for the case-control study was conducted at a tertiary 
hospital in Queensland. While a cohort study design would have been ideal to prospectively 
assess the characteristics of newly diagnosed patients who are prescribed an antidepressant, 
this study design was too time consuming for data collection and too expensive for this 
Master’s thesis. A cross-sectional study with direct involvement of the patients could have 
offered insight into the self-reported reasons for the prescription of the antidepressants, but 
was not taken consideration for master research because it was uncertain whether we could 
collect the number of sample at the limited time frame. Therefore considering all the possible 
options in research design and method, a retrospective matched case-control study was 
selected and offered the following advantages: abstractions of existing data from medical 
records without direct patient involvement; reasonable time required for ethics application 
and other clearances, no funding required in this project. 
From the systematic literature review, different data collection methods were identified 
including prescription record, dispensing record, medical chart or cancer registry, patient self-
reporting or health care professional reporting questionnaire. Dispensing record was the 
primary antidepressant data collection source from the hospital. However, data collection 
from the dispensing record of study characteristics in the study one, the pooled estimate of 
prevalence of antidepressants was low compared to other methods or overall pooled estimate. 
Additionally, it was unclear that patients took antidepressants regularly. To consider this 
limitation of this data collection method from dispensing record and to get current 
antidepressants prescription characteristics to cancer and non-cancer patients, we match the 
antidepressants dispensing record to the prescription record of inpatients from medical record 
of hospital.  
3.1 Introduction 
 
Cancer (16%) is the largest contributors to the burden of disease in Australia (AIHW, 2014). 
Co-occurrence with severe depression may lead to poorer outcomes and reduced survival 
(Hert et al., 2011). A large cohort study on adults (n= 89,574) in Australia 2006 to 2008 
showed that approximate 6.7% of cancer patients (n= 26,382) were suffering from high levels 
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of psychological disorder compared to 7.8% of non-cancer subjects (Banks et al., 2010). The 
incidence of depression is higher (9.8%, n= 713/7298) in first year of diagnosis of cancer 
than in non-cancer patients (0.8%, n= 112/14596) (Desplenter et al., 2012). 
Antidepressants are widely prescribed for the pharmacological treatment of depression and 
studies report that worldwide antidepressant prescribing has increased over the last three 
decades (Helgason et al., 2004, Moore et al., 2009, Pratt et al., 2011, Stephenson et al., 2012 
& Kantor et al., 2015). Antidepressants improve depressive symptoms; however, they also 
have adverse effects and can interact with cancer and non-cancer medications (Chan et al, 
2012; Gøtzsche, 2014; Yap et al., 2011). Various health professionals including physicians, 
oncologists, or psychiatrists have been identified as commonly prescribing antidepressants to 
cancer patients (Brelin et al., 2013). According to the Australian Institute of Health and 
Welfare on a population level, physicians prescribe 86% of antidepressants for the treatment 
of mental health in general, whereas psychiatrists prescribe only 8% and non-psychiatrists 
6% of prescription medicines (AIHW, 2012). There is also variation in doses of 
antidepressants by provider to the depressive patients. Usually it has been identified that 
psychiatrists prescribe higher doses of antidepressants to the patients compared to general 
practitioners in Australia (McManus et al., 2003). 
As described in chapter 2 a systematic literature search has been conducted and four case-
control studies reported that the prevalence of antidepressants to cancer patients is higher 
than non-cancer or patients with chronic disease conditions (Desplenter et. al., 2012; Jones et 
al., 2015; Ng et al, 2013b & Braun et al., 2015). The prevalence rate ranged from 9.8% to 
22.6%, with one study conducted on a large population-based cohort (Ng et al., 2013).  None 
of the studies reported, however, what type or dose of antidepressants was prescribed to the 
cancer patients, which group of health care professionals prescribed most frequently to cancer 
patient comorbid with depression, whether the follow-up is similar to what is recommended 
for mental health symptoms in people without cancer, or reported on the adverse effect or 
drug-drug interaction of antidepressants. 
3.2 Aims of the study 
 
From the systematic review and meta-analysis and research gap, the following research aims 
have been identified:- 
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Objective one: To describe the sociodemographic and clinical characteristics of cancer 
inpatients and non-cancer inpatients prescribed with antidepressants;  
Objective two: To compare the prescription profile of antidepressants in age and gender 
matched cancer and non-cancer inpatients;  
Objective three: To determine the occurrence of adverse effects or potential drug-drug 
interactions of antidepressants with other prescribed medicines prescribed to cancer patients. 
 
3.3 Research method 
 
3.3.1 Research design 
 
A retrospective age and sex matched cohorts of cancer and non-cancer patients were 
identified to determine nature of antidepressants use in these two groups. Socio-demographic, 
clinical and medicine records of cancer and non-cancer patients were abstracted from the 
hospital database system.  
3.3.2 Study setting 
 
This study was conducted at the Royal Brisbane & Women’s Hospital (RBWH) which is a 
tertiary referral hospital in Queensland, the largest provider of health care services, and one 
of the busiest mental health services in Queensland (Queensland Health, 2013). Data were 
collected from the electronic records of the Department of Pharmacy, RBWH.  
3.3.3 Study sample 
 
The inclusion and exclusion criteria for cases and control are described in table 3.1- 
Table 3.1: Inclusion and exclusion criteria of inpatients with antidepressant prescriptions 
 Inclusion criteria Exclusion criteria 
Cancer 
Patients 
 Patients >18 years 
 Any type of cancer diagnosed 
in the last ≤12 months 
 Recurrence or progression of cancer 
 Cancer diagnosed ≥12 months 
Non-cancer 
Patients 
 Patients >18 years 
 Age (±3 years) and gender 
matched case 
 Inpatient for the treatment of mental 
health problem 
 Previously diagnosis of cancer 
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3.3.4 Medications of interest 
 
The list of antidepressants was collected according to the Anatomical Therapeutic Chemical 
(ATC) classification code (ATC/DDD Index, 2016). The ATC categorised antidepressants 
(N06A) as: N06AA (Non-selective monoamine reuptake inhibitors), N06AB (Selective 
serotonin reuptake inhibitors), N06AF (Monoamine oxidase inhibitors, non-selective), 
N06AG (Monoamine oxidase A inhibitors) or N06AX (Other antidepressants). Generic 
names of the medications prescribed for patients receiving cancer treatment or treatment for 
other diseases were collected. Additionally the date of prescription of each medicine, dose, 
and dosage form was extracted. A list of ceased medication was also collected. The number 
of other medications prescribed during hospitalisation, including supplementary or over the 
counter medicines, was also extracted. The recommended dose of antidepressant was 
determined from the defined daily dose present in the ATC classification code.   
3.3.5 Diagnosis of depression 
 
A diagnosis of depression was identified through a review of all information contained in the 
hospital medical record including correspondence letters from general practitioners or other 
health professionals, RBWH internal referral letters, patient progress reports, patient self-
report forms, discharge report, diagnostic test of depression report, or health assessment 
records. It was also extracted whether depression was reported as a comorbidity or pre-
admission medical history.   
For many patients depression was formally assessed at admission using the Patient Health 
Questionnaire (PHQ-2) most commonly conducted by a nurse as part of the standardised 
patient risk assessment (Appendix B: Patient Health Questionnaire). If the total score of the 
PHQ-2 is ≥3 out of 6 or the nurse is concerned about the patient’s mood, a referral of the 
patient to the medical team to consider psychology or psychiatry treatment will be arranged. 
It is also recommended to include information about the PHQ results in the discharge 
summary to general practitioner.  
3.3.6 Other variables 
 
Socio-demographic variables  
Age, sex (Male), country of birth (Australian, non-Australian), patient status (alive, 
deceased), insurance (yes, no), alcohol and smoking status (current, past user, never), marital 
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status (married, widow, de facto, divorced/ separated, never married), living status (family, 
other, alone), employment (yes, no), concession status (yes, no) were extracted for case and 
control patients and used as adjustment variables in data analysis where applicable.   
Clinical variables 
The date of diagnosis with cancer was determined from the referral letter by health care 
professional to the hospital or progress report by hospital practitioner. Other clinical variables 
including cancer status (type of cancer, type of cancer treatment), personal and family history 
of depression (yes, no), depression information (date of diagnosis, referral for counselling or 
psychotherapy, antidepressants prescriber information, antidepressants start date), 
comorbidities, other mental problem, pain assessment, mental health assessment (PHQ-2 test 
or other) and their follow-up, other mental health assessment test, allergic or adverse reaction 
to antidepressants or other medicines were considered for data collection. Comorbidities of 
disease were categorised according to the International Classification of Diseases (ICD) 
(WHO, 2015). 
3.3.7 Indication of antidepressant 
Antidepressant prescribed in the treatment of depression or other mental problem was 
determined from the information of depression present as comorbidity or pre-medical history 
in any documents of hospital database system. Indication of antidepressant was categorised 
into three ways-  
1. Depression- Depression recorded as comorbidity in any documents of database. Only 
depression or depression with other mental health problems also was considered in this 
category. 
2. Other mental health problem- No information about depression, but recorded other mental 
health problem was considered in this category. 
3. Not recorded- No information of depression or any mental health problem in any 
documents of database was considered as not recorded.  
3.3.8 Ethical clearance and other approval 
 
The study was considered low and negligible risk (LNR) research by the Royal Brisbane 
Women’s Hospital Human Research Ethics Committee (HREC) as there was no contact or 
involvement of patients during the data collection process in the hospital throughout the 
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whole study timeline. There was no involvement of children and the age of the participants 
was18 years or older. Two ethical clearances were obtained to conduct the data collection 
process of this pilot retrospective case-control study- 1) Royal Brisbane Women’s Hospital 
(RBWH) and 2) Queensland University of Technology (QUT) ethics committees.  
Low or Negligible Risk research application for Ethical Review (Reference number: 
HREC/15/QRBW/137) was submitted to the RBWH Human Research Ethics Committee 
(HREC) with the approval from the Department of Pharmacy, RBWH to undertake the 
research (Appendix C: RBWH-HREC approval letter). The ethics application approval 
number was EC00172. After getting approval from the RBWH-HREC, Human‐
Administrative Review application was submitted to the Queensland University of 
Technology human ethics research committee and got the approval to conduct the research at 
the RBWH (Appendix D: QUT-HREC approval email). The QUT approval number was 
1500000417.  
To access the identifiable data and health information held by Queensland Health, Public 
Health Act – Application was submitted after consultation with the data custodian of RBWH 
who approved the application (Appendix E: Public Health Act approval letter) to access read 
only database present in the Department of Pharmacy, RBWH. The approval number was 
RD005678.  
A research data agreement was negotiated between QUT and Metro North Hospital and 
Health Service (Department of Pharmacy, Royal Brisbane and Women’s Hospital). The 
Research Governance Office provided the approval for all the documents including RBWH 
HREC, Public Health Act application, protocol of the study, data collection tool, letter of 
support from the from Department of Pharmacy, RBWH and curriculum vitae of Principal 
Investigator (Appendix F: Research Governance Office approval letter). 
3.4 Data collection 
 
Data were collected from the integrated electronic Medical Record (ieMR) database in the 
Department of Pharmacy, RBWH. The sources of each data collection as extracted are listed 
in the following Table 3.2. 
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Table 3.2: Sources of data from RBWH   
Data feature Source  
A. Sociodemographic status 
Age, Sex, Patient status, Country of 
origin, Religion, Marital status  
ieMR patient information cover page 
Living status Health risk assessment questionnaire,  
Occupational therapy initial assessment,  
Progress report, 
Alcohol/Smoking status Health risk assessment questionnaire 
Employment, Concession, Insurance  Occupational therapy initial assessment, 
Patient Election form-Administration, 
Patient registration form 
B. Clinical record 
Cancer information- date of diagnosis, 
type 
Comorbidities 
Correspondence letters from General Practitioner or 
other practitioner,  
External hospital reference,  
RBWH internal reference letter,  
Progress report, 
Discharge report of RBWH and external hospital  
Allergic or adverse reaction ieMR patient information page, 
Health risk assessment questionnaire 
Depression information- Type, History 
Other mental health problem 
Correspondence letters from General Practitioner or 
other practitioner, 
Hospital internal reference letter,  
Progress report,  
Health risk assessment questionnaire 
Patient Health Questionnaire (PHQ-2) Health risk assessment questionnaire 
c. Medicines record 
Antidepressants Dispensing record complemented by prescription record,  
Progress record,  
Any correspondence letter from RBWH internal or 
external reference, 
Medication Action Plan (MAP) 
Other medicines RBWH prescription record,  
Progress record,  
Any correspondence letter from RBWH internal or 
external reference 
Medication Action Plan (MAP) 
 3.4.1 Selection of sample 
 
Data were extracted from patients who had been admitted as inpatients to the cancer, general 
medical, surgical or haematological wards of RBWH. Admission had to occur in the hospital 
in the timeline of January 2014 to July 2015 for the treatment of cancer or post-treatment 
procedure. Control patients were inpatients at the hospital for the treatment of chronic disease 
or accidental injury.   
Initially cancer and non-cancer patients were selected at random from those that had a record 
of antidepressants present in the dispensing record of the RBWH. Cancer cases were searched 
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according to the inclusion criteria of patient diagnosed with new cancer within the past 12 
months and prescribed antidepressants. Prescription of antidepressants within 12 months of 
cancer diagnosis was confirmed from the earliest date of dispensing record or prescription 
record. Cancer cases were excluded if the patients had progressive disease or recurrence of 
cancer or were prescribed antidepressants 12 months or more after cancer diagnosis.  
Control patients prescribed antidepressants were selected then by age and gender matching 
the cancer patients. Control patients were inpatients with any chronic disease condition from 
general and surgical ward. During the matching of age, controls were selected with the 
closest age to the cancer patients; the maximum age band was ±3 years. 
3.4.2 Clinical record 
 
Extracted data including comorbidities, allergic or adverse drug reaction, depression record 
or other mental health problems, all collected from the correspondence letters from General 
Practitioner or other practitioner, external hospital reference, RBWH internal reference letter, 
progress report, RBWH discharge report (Table 3.2). Comorbidity or pre-medical history of 
depression was collected from the practitioner referral information present in the database.  
3.4.3 Medicine record 
 
Antidepressants as well as other medications prescribed to the patients were collected from 
the prescription record of the ieMR database. The list of antidepressants was collected 
according to the ATC Classification System. Initial source of antidepressants profile was the 
dispensing record. Data from the dispensing record were compared with the prescription 
record and any other hospital documents present in the database. Additionally date of 
prescription of each medicine and their dose as well as dosage form including oral, 
intravenous, topical were extracted. A list of medications ceased in the hospital was also 
extracted. Over the counter (OTC) medicines and supplementary lists were also collected 
from the hospital prescription record and the number of these counted in the total number of 
medications list. 
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3.5 Data quality and management 
 
3.5.1 Confidentiality and security 
 
Patients were not involved in person or contacted for this research. However, data were 
collected through the identifiable Medical Reference Number (MRN) from hospital to select 
cases and matched controls. Every person was assigned in the data collection materials with 
an individual unique but meaningless identification code, while no names or age or any 
potentially identifiable codes were extracted.  
After collecting the data, materials were kept in a secure place of the Research office in the 
Department of Pharmacy, RBWH. The outcomes of the data collection efforts are presented 
in aggregated format only to ascertain privacy of the patients. 
3.5.2 Data entry 
 
The ieMR is a read-only access electronic patient clinical and medicine records database. 
Initially extracted data were entered in the primary paper-based data collection form 
(Appendix G: Data collection form). Patient identification number, age and gender were 
inserted into the separate sheet to allow matching to age and gender based control 
participants. Primary de-identified data were entered into the spreadsheet for data store and 
analysis.  
3.5.3 Data storage 
 
Dispensing record materials as well as information of patient age and gender match sheet was 
stored in a secured place of research office of Department of Pharmacy, RBWH. Primary de-
identified data collection materials were stored in the secured place of Principal Supervisor 
office at QUT. De-identified electronic data were saved on the secured drive of the QUT 
university network. 
3.6 Data analysis 
 
Conditional logistic regression was used as the statistical analysis method for the 
retrospective, matched case-control study. Each case was paired with one age and gender 
matched control to efficiently determine association of categorical variables (Breslow & Day, 
1980; Bruce et al., 2008 & Rose and van der Laan, 2009). This analysis method is superior to 
reduce the bias of sample selection (Rothman and Greenland, 1998). The limitations of using 
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conditional logistic regression are that it is difficult to generate conditional distribution of 
statistics for continuous variables. This limitation can be overcome by converting continuous 
variables into categorical variables. Another limitation is that conditional logistic regression 
results in wider confidence intervals compared to standard logistical regression (Heinze, 
2006).   
Statistical analysis was conducted by using the Statistical Package for the Social Science 
(SPSS), Version 23. Missing variables were denoted as ‘not recorded’ covariate. For each 
objective the following analysis were conducted-  
Objective One: To describe the sociodemographic and clinical characteristics of cancer 
inpatients and non-cancer inpatients prescribed with antidepressants 
Descriptive analyses (frequencies, percentage for categorical variables) were conducted to 
describe the distribution of each sociodemographic variable of cases and controls. 
Sociodemographic characteristics were compared through categorical variables by contrast 
between case and control using conditional logistic regression. Odds ratio (OR), 95% 
confidence interval (CI) and p-values were reported for each covariate. Matched cox 
regression of survival analysis was used to describe the data.  
Frequencies, percentages and conditional logistic regressions were also used to describe the 
clinical characteristics (including type, number and treatment of cancer; type of comorbidity) 
of cases and control. The type, number and treatment of cancer were presented by frequencies 
and percentages.    
Objective Two: To compare the prescription profile of antidepressants in age and gender 
matched cancer and non-cancer inpatients  
Statistical significance and clinical importance were considered to determine the association 
between case and control of sample. Conditional logistic regression was used to analyse the 
association of the matched case-control sample. Statistical significance was determined by p 
value (<0.05). Frequency was used to describe the prescription profile of antidepressants of 
cancer and non-cancer patients. The profile of inpatients of cancer and non-cancer patients 
who were prescribed antidepressants was described by using covariate analysis (including 
antidepressants used, number and ceased of antidepressants, referral refer to medical team or 
general practitioner to consider psychology or psychiatry treatment, patient seen by 
psychologist and psychiatrist, suicidal ideation, number of comorbidities and medicines, pain, 
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depression test follow-up). A descriptive prescription profile of antidepressants was tabulated 
including type and dose of antidepressants, change of dose with the mental health status of 
case and control, and by whether the patient received the prescription due to depression, other 
mental problem and no mental problem.  
Objective Three: To determine the occurrence of adverse effect or potential drug-drug 
interaction of antidepressants with other prescribed medicines to cancer patients 
The occurrence of adverse events and the exact symptoms was determined from the 
information present in the hospital database (Table 3.2) or patient self-report (indicated name 
of antidepressants as well as symptoms).  Concomitant use of antidepressants and other 
medications prescribed at the same date and their potential drug-drug interactions were 
identified from drug-drug interaction present in the Australian Medicines Handbook, even if 
no actual adverse events were noted in the hospital database (Australian Medicines 
Handbook, 2015). 
3.7 Result 
 
Sample selection and inclusion 
507 records were screened, after screening for the inclusion criteria and matching 
requirements, only 75 cases and 75 controls remained for the final analyses. Reasons for 
exclusions are described below and shown in Figure 3.1. 
The records of 226 cancer patients with antidepressants were selected from the dispensing 
record taking antidepressants (Figure 3.1). Of these records had to be excluded because the 
diagnosis of cancer had been obtained more than 12 months ago, repeat of sample, no 
matching control, not visiting in the hospital or outpatients or no clear information about 
cancer date of diagnosis. 
The records of 281 non-cancer patients were selected from the dispensing record of 
antidepressants at the same period of time. 75 controls were able to be matched with a 
maximum ±3 year age and gender of the cancer sample, after non-matching controls, controls 
who also had a cancer diagnosis, or other exclusion criteria were applied. 
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Figure 3.1: Flow chart of sample selection and inclusion 
Objective One: Compare the profile of inpatients of cancer and non-cancer inpatients who 
are prescribed antidepressants 
The comparison between cancer and non-cancer patients with antidepressants on socio-
demographic and clinical characteristics is described in table 3.3. 
The average age of both cancer and non-cancer patients was 60 years; around two-thirds were 
65 years or older. About half of the sample were male (n=36, 48%). About one-third of the 
cancer sample (n= 24/75, 32%) was deceased within 18 months (whole time-line of the 
study) of cancer diagnosis, whereas only 5.4% of non-cancer patients died during the timeline 
of the study. This is reflected in the significantly greater odds of death in the cancer sample 
(n=24, 33% vs n=4, 5.4%; OR 65.29 (95% CI 1.79-2378.62); p= 0.02). Cancer patients 
(n=17, 22.7%) were more likely to have private insurance than non-cancer patients (n=11, 
14.7%). 
 
  
Assessed for eligibility (n= 507) 
January 2014-July 2015  
Cancer patients (n= 226) Non-cancer patients (n= 281) 
Excluded: 
 Cancer recurrence/ 
progression or cancer 
diagnosed ≥12 months  
(n= 71) 
 Duplicate sample (n= 12) 
 No result found/ No visit/ 
Outpatient (n= 38) 
 No clear information about 
inclusion criteria (n= 19) 
 
Excluded: 
 Mental health patient  
(n= 11) 
 Duplicate sample (n= 11) 
 Previously diagnosed 
with cancer (n= 35) 
 
Cancer patients after meeting 
inclusion criteria (n= 86) 
Non-cancer patients after meeting 
inclusion criteria (n= 224) 
Cancer patients (n= 75) Non-cancer patients (n= 75) 
Gender matched 
Age matched (Same 
age, n= 29; ±1 year age; 
n= 24, ±2 year age, n= 
21; ±3 year age, n= 1) 
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Table 3.3: Socio-demographic & clinical status of cancer and non-cancer patients 
prescribed with antidepressants 
Characteristics 
Cancer, 
n=75(%) 
Non-cancer, 
n=75(%) 
OR (95% CI) p value 
Average age (range years) 60(23-86) 60(22-88)   
Gender 
Male 
 
36 (48.0) 
 
36 (48.0) 
  
Patient status 
Alive 
Deceased 
 
51 (68.0) 
24 (32.0) 
 
71 (94.6) 
4 (5.4) 
 
- 
65.29 (1.79-2378.62) 
 
- 
0.02 
Country of birth 
Australia 
Non Australian 
 
55 (73.3) 
20 (26.7) 
 
61 (81.3) 
14 (18.7) 
 
- 
1.67 (0.73-3.81) 
 
- 
0.22 
Private insurance 
Yes 
No/ Not recorded 
 
17 (22.7) 
58 (77.3) 
 
11 (14.7) 
64 (85.3) 
 
- 
0.6 (0.26-1.37) 
 
- 
0.26 
Alcohol status 
Never 
Current user 
Past user 
Not recorded 
 
30 (40.0) 
35 (46.6) 
5 (6.7) 
5 (6.7) 
 
38 (50.7) 
24 (32.0) 
8 (10.7) 
5 (6.6) 
 
- 
1.96 (0.88-4.35) 
1.02 (0.28-3.71) 
1.23 (0.33-4.60) 
 
- 
0.10 
0.97 
0.76 
Smoking status 
Never 
Current user  
Past user 
Not recorded 
 
27 (36.0) 
21 (28.0) 
24 (32.0) 
3 (4.0) 
 
18 (24.0) 
29 (38.7) 
22 (29.3) 
6 (8.0) 
 
- 
0.45 (0.19-1.10) 
0.81 (0.34-1.94) 
0.37 (0.08-1.59) 
 
- 
0.08 
0.64 
0.18 
Employment status 
Yes 
No/Not recorded 
 
24 (32.0) 
51 (68.0) 
 
12 (16.0) 
63 (84.0) 
 
- 
0.37 (0.15-0.87) 
 
- 
0.02 
Age/Disability pensioner 
Yes 
No/Not recorded 
 
41 (54.7) 
34 (45.3) 
 
52 (69.3) 
23 (30.7) 
 
- 
2.2 (1.01-4.88) 
 
- 
0.05 
Marital status 
Married 
Widow 
De facto 
Divorced/ Separated 
Never married 
Not stated 
 
32 (42.7) 
7 (9.3) 
3 (4.0) 
22 (29.4) 
10 (13.3) 
1 (1.3) 
 
15 (20.0) 
7 (9.3) 
3 (4.0) 
21 (28.0) 
26 (34.7) 
3 (4.0) 
 
- 
0.49 (0.13-1.89) 
0.58 (0.07-4.75) 
0.53 (0.21-1.35) 
0.20 (0.17-0.56) 
- 
 
- 
0.30 
0.61 
0.19 
0.002 
- 
Living status 
Family 
Alone 
Other
1
 
Not recorded 
 
43 (57.3) 
21 (28.0) 
7 (9.3) 
4 (5.4) 
 
22 (29.3) 
25 (33.3) 
19 (25.4) 
9 (12.0) 
 
- 
0.37 (0.16-0.90) 
0.16 (0.05-0.50) 
0.23 (0.06-0.86) 
 
- 
0.03 
0.002 
0.03 
Abbreviations: CI= Confidence Interval; OR=Odds Ratio. 
1
Indicated living at shared place, community home, 
aged care, retirement village, nursing home or homeless. No statistics reported as age, gender were used for 
matching. Italicized entries indicate significant results.  
 
There was no significant difference between cases and controls in current alcohol use- 
socially or regularly. More than half of the non-cancer patients (n=38/75) were never 
drinking alcohol, whereas the percentage was somewhat smaller in cancer patients (n=30, 
40%). Overall, 60% (n= 45/75) of cancer patients were current or past smokers and about 
one-third of them (n= 18) were diagnosed with cancer of the respiratory tract and oral cavity 
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and 5 patients were diagnosed with lung cancer. Conversely, more than two-third of non-
cancer patients (n=51, 68%) were current or past user of smoking.   
About one-third of the cancer patients (n=24, 32%) were employed, compared to only 16% 
(n=12) for non-cancer patients. Other patients in both groups were unemployed (n=51, 68% 
vs n= 63, 84%; p= 0.02) or did not hold aged or disability concession (n= 34, 45.3% vs n= 
23, 30.7%; p= 0.05). About 57.3% (n=43) of cancer patients were living with their family, 
whereas only 29.4% (n=22) of non-cancer patients were married and lived with family. 
Cancer patients were significantly less likely to have never been married compared to non-
cancer patients (n=10, 13.3% vs n= 26, 34.7%; p= 0.002). 
The clinical status of cancer and non-cancer patients is presented in table 3.4 and includes the 
information of cancer profile for cases and type of comorbidities for both groups. A quarter 
of the cancer patients were diagnosed with haematological cancer (n=19, 25.3%) and other 
cancer diagnoses were cerebral (n=9, 12%), breast, lung or face/oesophagus/tongue (n=8, 
10.7% each) cancer. All cancer patients were receiving chemotherapy (n=24, 32%) or 
radiotherapy (n=22, 29.3%) or both (n=24, 32%). 
A wide range of comorbid conditions were identified in the cancer and non-cancer patients 
(Table 3.4). The proportion of chronic diseases was consistent across the two groups 
including circulatory disease (n= 43, 57.3% vs n= 41, 54.7%; hypertension or arterial 
fibrillation), endocrine disorder (n= 31, 41.3% vs n= 28, 37.3%; diabetes mellitus, 
hypothyroidism), respiratory disease (n= 27, 36% vs n= 34, 45.3%; asthma), blood disorder 
(n= 20, 26.7% vs n= 24, 32%; hyperlipidaemia) or bone and joint disease(n= 15, 20% vs n= 
20, 26.7%; arthritis) (Table 3.4). 
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Table 3.4: Clinical status of cancer patients & non-cancer patients 
 Cancer, 
n=75(%) 
Non-cancer, 
n=75(%) 
OR (95% CI) p value 
Cancer Type 
Blood 
Brain 
Breast 
Face/Oesophagus/Tongue 
Lung 
Gynaecological 
Bowel & Colorectal 
Oropharyngeal 
Other 
 
19 (25.3) 
9 (12.0) 
8 (10.7) 
8 (10.7) 
8 (10.7) 
6 (8.0) 
5 (6.6) 
4 (5.3) 
8 (10.7) 
 
  
Number of cancer 
Single cancer 
More than one cancer 
 
64 (85.3) 
11 (14.7) 
 
  
Cancer Treatment 
Chemotherapy 
Radiotherapy 
Both 
 
24 (32.0) 
22 (29.3) 
29 (38.7) 
 
  
Circulatory diseases 
Yes 
No  
Not recorded
1
 
 
43 (57.3) 
27 (36.0) 
5 (6.7) 
 
41 (54.7) 
34 (45.3) 
0 
 
- 
0.83(0.42-1.65) 
- 
 
 
0.60 
Endocrine diseases 
Yes 
No 
Not recorded 
 
31 (41.3) 
39 (52.0) 
5 (6.7) 
 
28 (37.3) 
47 (62.7) 
0 
 
- 
0.76(0.40-1.46) 
- 
 
 
0.41 
Respiratory diseases 
Yes 
No 
Not recorded 
 
27 (36.0) 
43 (57.3) 
5 (6.7) 
 
34 (45.3) 
41(54.7) 
0 
 
- 
1.31(0.68-2.51) 
- 
 
 
0.41 
Digestive diseases 
Yes 
No 
Not recorded 
 
24 (32.0) 
46 (61.3) 
5 (6.7) 
 
32 (42.7) 
43 (57.3) 
0 
 
- 
1.43(0.72-2.83) 
- 
 
 
0.30 
Blood disorder 
Yes 
No 
Not recorded 
 
20 (26.7) 
50 (66.6) 
5 (6.7) 
 
24 (32.0) 
56 (68.0) 
0 
 
- 
1.23(0.59-2.56) 
- 
 
 
0.58 
Bone & joint disorder 
Yes 
No 
Not recorded 
 
15 (20.0) 
55 (73.3) 
5 (6.7) 
 
20 (26.7) 
55 (73.3) 
0 
 
- 
1.25(0.58-2.68) 
- 
 
 
0.56 
Nervous system diseases 
Yes 
No 
Not recorded 
 
14 (18.7) 
56 (74.6) 
5 (6.7) 
 
21 (28.0) 
54 (72.0) 
0 
 
- 
1.33(0.56-3.16) 
- 
 
 
0.51 
Renal system disease 
Yes 
No 
Not recorded 
 
10 (13.3) 
60 (80.0) 
5 (6.7) 
 
12 (16.0) 
63 (84.0) 
0 
 
- 
1.25(0.49-3.17) 
- 
 
 
0.64 
Abbreviations: CI= Confidence Interval; OR=Odds Ratio
.1
No information of any comorbidity in the database. 
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Objective Two: Compare the prescription profile of antidepressants in age and gender 
matched cancer and non-cancer inpatients 
The comparative profile of cancer and non-cancer patients with regards to the profile of 
antidepressants is described in table 3.5. There were significant differences in the odds of 
being prescribed antidepressants for the treatment of depression (n= 50, 66.7% vs n= 59, 
78.6%; p= 0.05) and other mental health problems (n= 8, 10.6% vs n= 11, 14.7%; p= 0.02) 
between the cancer and non-cancer patients. No information of any mental health problem 
was present in groups (n=17, 22.7% vs n=5, 6.7%). Antidepressant used in the treatment of 
depression and other mental problem was identified from the corresponding letter, progress 
report, and hospital internal reference letter or health risk assessment questionnaire (Table 
3.2). Other mental problem was including anxiety, bipolar disorder (BPD), confusion & 
agitation, schizophrenia, chronic fatigue, personality or obsessive compulsive disorder. 
Two-third of the cancer patients (n=50, 66.7%) were prescribed antidepressants for the 
treatment of depression denoted by health care professionals as a comorbidity or in the pre-
admission medical history presented in the clinical record (Table 3.5). However, when we 
looked at the prescription record of antidepressant, other mental health problems were 
mentioned as reasons for prescription of antidepressants. Only 14% (n=7/50) of cancer 
patients were prescribed antidepressants for the treatment of depression mentioned in the 
prescription record filled-up by health care providers in hospital. Another 12% of cancer 
patients (n=6/50) were stated in the prescription record for other mental problem including 
anxiety, bipolar disorder (BPD) or side-effects of cancer treatment including problems with 
sleep, appetite, and pain.    
A greater proportion of non-cancer patients (n=20/75, 26.7%) were prescribed two or more 
antidepressants compared to the cancer patients (n=15/75, 20.0%). Three cancer patients and 
one non-cancer patient had notes that they had ceased antidepressants. There was no 
significant difference between cancer and non-cancer patients regarding the proportion with a 
referral to the medical team for psychological or psychiatry treatment and a similar 
proportion of patients were already seen or consulted by a psychologist or psychiatrist or 
other mental health services in the hospital or community.  
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Table 3.5: Profile of cancer and non-cancer inpatients prescribed antidepressants 
Profile of inpatients Cancer, 
n=75(%) 
Non-cancer, 
n=75(%) 
OR(95% CI) 
p 
value 
Indication for antidepressants
1
 
Depression 
Other mental health problem 
Not recorded 
 
50 (66.7) 
8 (10.6) 
17 (22.7) 
 
59 (78.6) 
11 (14.7) 
5 (6.7) 
 
- 
0.81 (0.30-2.17) 
4.56 (1.30-15.93) 
 
- 
0.67 
0.02 
Number of antidepressant prescriptions in the 
medical record 
One antidepressant 
More than one antidepressant 
 
 
60 (80.0) 
15 (20.0) 
 
 
55 (73.3) 
20 (26.7) 
 
 
- 
0.70 (0.34-1.48) 
 
 
- 
0.35 
Ceased antidepressant
2
 
Yes 
No 
 
3 (4.0) 
72 (96.0) 
 
1 (1.3) 
74 (98.7) 
 
- 
0.50 (0.04-5.51) 
 
- 
0.57 
Referred to medical team or GP to consider 
psychology or psychiatry treatment 
Yes 
No 
 
 
 
13 (17.3) 
62 (82.7) 
 
 
 
15 (20.0) 
60 (80.0) 
 
 
 
- 
1.20 (0.52-2.78) 
 
 
 
- 
0.67 
Patient seen/consulted by psychologist or 
psychiatrist in hospital and community 
Yes 
No 
 
 
 
7 (9.3) 
68 (92.7) 
 
 
 
10 (13.3) 
65 (86.7) 
 
 
 
- 
1.50 (0.53-4.21) 
 
 
 
- 
0.44 
Patient under mental health services 
Yes 
No 
 
3 (4.0) 
72 (96.0) 
 
8 (10.7) 
67 (89.3) 
 
- 
2.67 (0.71-10.05) 
 
- 
0.15 
Suicidal ideation 
Yes 
No 
 
6 (8.0) 
69 (92.0) 
 
16 (21.3) 
59 (78.7) 
 
- 
2.67 (1.04-6.81) 
 
- 
0.04 
Number of comorbidities 
1-2 
3-4 
5-6 
>7 
Not recorded
3
 
 
23 (30.7) 
28 (37.3) 
16 (21.3) 
3 (4.0) 
5 (6.7) 
 
18 (24.0) 
24 (32.0) 
23 (30.7) 
10 (13.3) 
0 
 
- 
0.90(0.38-2.14) 
0.56 (0.22-1.42) 
0.17 (0.03-0.88) 
- 
 
- 
0.81 
0.22 
0.03 
- 
Total number of medicines and 
supplementaries prescribed during hospital stay 
0-10 
11-20 
21-30 
≥31 
 
 
6 (8.0) 
26 (34.7) 
30 (40.0) 
13 (17.3) 
 
 
14 (18.7) 
37 (49.3) 
18 (24.0) 
6 (8.0) 
 
 
- 
1.58 (0.51-4.84) 
3.52 (1.11-11.21) 
4.82 (1.10-21.11) 
 
 
- 
0.42 
0.03 
0.04 
Pain 
Yes 
No 
Not recorded 
 
44 (58.7) 
22 (29.3) 
9 (12.0) 
 
37 (49.3) 
31 (41.3) 
7 (9.3) 
 
- 
0.58 (0.28-1.21) 
1.22 (0.33-4.49) 
 
- 
0.15 
0.76 
Depression test (PHQ-2) follow-up 
Yes 
No 
Not recorded 
 
32 (42.7) 
29 (38.6) 
14 (18.7) 
 
17 (22.7) 
39 (52.0) 
19 (25.3) 
 
- 
0.39 (0.17-0.86) 
0.33 (0.11-0.95) 
 
- 
0.02 
0.04 
Abbreviations: CI= Confidence Interval; OR=Odds Ratio. Italicized entries indicate significant results. 
1
Based 
on comorbidity or pre- medical history of patients. 
2
The sources of ceased antidepressant were patient self-
report or referral from other hospital. 
 3
Excluded from the statistical analysis. 
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A significant number of patients reported suicidal ideation, but the proportion of cancer 
patients was lower than non-cancer patients (n=6, 8% vs n= 16, 21.3%). A notable result was 
identified with regards to the depression test (PHQ-2) follow-up, with significantly more 
cancer patients having such follow-up notes (n=32, 42.7% vs n=17, 22.7%). 
Table 3.6 provides prescription characteristics of antidepressants to cancer and non-cancer 
patients. Supplementary table 2.6 shows the type and dosage information of prescribed 
antidepressants for each group. The total number of antidepressant prescriptions was 90 for 
cancer patients and 95 for non-cancer patients. Mirtazapine (n=11/50) was the most 
commonly prescribed antidepressants for the treatment of depression to cancer patients 
followed by duloxetine (n=9/50), and escitalopram (n=8/50). Non-cancer patients were most 
commonly prescribed desvenlafaxine (n=15/59), mirtazapine (n=11/59), or escitalopram 
(n=8/59) for the treatment of depression. Cancer patients identified as no mental health 
problem were also prescribed mirtazapine (n=6/17) more, followed by amitriptyline (n= 
3/17), fluoxetine (n= 3/17), meclobemide (n= 2) was prescribed only to cancer patients and 
nortriptyline (n= 2) only to non-cancer patients (Supplementary table 2.6).  
Variations of dose of antidepressant from the recommended therapeutic dose were identified 
in both case and control patients (Table 3.6). The recommended dose of antidepressants 
(n=24/59) was prescribed more to the cancer patients for the treatment of depression 
compared to non-cancer patients (n=29/75). Non-cancer patients (n= 34/75) who received 
antidepressants for depression were prescribed the medication at higher than recommended 
dose compared on 22 cancer patients. This could indicate that dose adjustments are less 
commonly conducted in cancer patients and needs to be investigated further in future 
research. 
The number of antidepressants prescribed to a patient and change of dose during the whole 
study timeline was not significantly different in cancer and non-cancer patients. Only five 
non-cancer patients were prescribed with a changed antidepressant from the previous one 
compared to two cancer patients.   
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Table 3.6: Prescription characteristics of antidepressants to cancer and non-cancer 
patients  
  Cancer Non-cancer 
  
Depressive 
patient 
(n= 50) 
Other 
mental 
health 
problem 
(n= 8) 
No 
information 
of mental 
health 
problem 
(n= 17) 
Depressive 
patient  
(n= 59) 
Other 
mental 
health 
problem  
(n= 11) 
No 
information 
of mental 
health 
problem  
(n= 5) 
Antidepressant 
prescription (n) 
59 10 21 75 13 7 
Most 
commonly 
prescribed 
antidepressant  
Mirtazapine 
(n=11) 
Mirtazapine 
(n=5) 
Mirtazapine 
(n=6) 
Desvenlafaxine 
(n=15) 
Venlafaxine 
(n=3) 
Mirtazapine 
(n=3) 
Variation of dose 
Lower dose 13 4 5 12 3 3 
Recommended 
dose
 1
 
24 6 9 29 4 2 
Higher dose 22 - 7 34 6 2 
Number of antidepressant 
1 41 6 13 52 9 3 
≥2 9 2 4 11 2 2 
Change of dose 11 - - 10 1 1 
Change of 
antidepressant 
1 - 1 5 - - 
1
indicated type and dose of antidepressants according to Anatomical Therapeutic Chemical (ATC) Classification 
System. Italicized entries indicated the recommended dose. 
Objective Three: Occurrence of adverse effects or potential drug-drug interactions of 
antidepressants with other prescribed medicines to cancer patients 
Four cancer patients and three non-cancer patients experienced adverse events attributed to 
their antidepressants according to clinical record (Table 3.2). Only two cancer patients 
reported symptoms of adverse events including tongue swelling (Venlafaxine) and nausea 
(Escitalopram). 
There were no specific notes by health care professionals identifying drug-drug interactions 
in the clinical or medicine record. However, a number of cancer patients were prescribed 
medications that were contra-indicated with their antidepressant due to the potential for drug-
drug interaction between antidepressants and other prescribed medicines as listed in table 3.7. 
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About one-third of cancer patients (n= 23) and more than one-fourth non-cancer patients 
(n=18) had identified as potential drug-drug interaction with their prescribed antidepressant. 
Table 3.7: Probable drug-drug interactions in cancer patients 
Antidepressant 
Contra-
indicated 
medication 
Probable drug-drug interaction 
Cancer 
(n=23)
1
 
Non-
cancer  
(n= 18)
1
 
Amitriptyline Fluoxetine 
Fluoxetine inhibits hepatic 
metabolism of amitriptyline 
caused toxicity. 
2 - 
Fluoxetine Warfarin Risk of bleeding 1 2 
Mirtazapine Levodopa Psychosis, suicidal ideation 1 1 
SSRIs
2
 Heparin Risk of bleeding 7 4 
SSRIs
2
 Oxycodone Risk of serotonin syndrome 12 7 
SSRIs
2
 NSAIDs
3
 
Risk of upper gastrointestinal 
bleeding 
3 5 
Venlafaxine Heparin Risk of bleeding 2 1 
Venlafaxine 
Amoxicillin-
Clavulanic 
acid 
Risk of serotonin syndrome 1 - 
1
Patients may suffer from two or more drug-drug interactions. 
2
Selective serotonin reuptake inhibitors (SSRIs). 
3
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
3.8 Discussion 
 
3.8.1 Overview 
 
The main findings of this case-control study include the significant differences between cases 
and controls with respect the indication of antidepressants as well as variation in type of 
antidepressants. There were also between group differences in a number of socio-
demographic (patient status, suicidal ideation, employment or concession status) and clinical 
characteristics (comorbid chronic disease conditions), as might be expected. 
More non-cancer patients were prescribed antidepressants for the treatment of depression, 
whereas mixed reasons for indication of antidepressants including anxiety, BPD as well as 
physical symptoms such as problems with sleep, appetite or pain were identified from the 
prescription records of cancer patients. The proportion of patients for whom no record of 
mental health problems was found in their clinical record was higher in cancer patients (n= 
17, 22.7%) than non-cancer patients (n= 5, 6.7%) (Table 3.5). In considering the type of 
antidepressants, mirtazapine was prescribed more to cancer patients for the treatment of 
depression (n= 11) and unidentified reasons (n= 6) (Table 3.6). This is consistent with a 
previous study (Farriols et al., 2012) and likely due to mirtazapine being well-tolerated and 
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safe antidepressants for daily administration. Additionally it shows potential effect on pain 
besides depression (Freynhagen et al., 2006), and has a role in the treatment of 
chemotherapy-induced loss of appetite (Australian Medicines Handbook, 2015 & Griffin et 
al., 1996).  
The proportion of patients who were unemployed or had concession status prescribed with 
antidepressants was high in both groups. This result is in line with a study conducted in 
Australia from 2003-2005 which showed that patients with low socio-economic status group 
more commonly utilise antidepressants compared to patients with higher socioeconomic 
status (p<0.001) (Page et al. 2009). Future longitudinal studies could seek to clarify this 
relationship and whether better access to behavioural therapy or supportive care could 
alleviate this inequitable use of antidepressants by socioeconomic status.  
It must be of concern to health professionals that so many patients had suicidal ideation 
despite taking antidepressants. The proportion was higher in non-cancer patients (21.3%, n= 
16), but still considerable among cancer patients (8%, n= 6).  Choice of antidepressants 
prescribed by health care professional also varied between the groups. Desvenlafaxine is used 
for the treatment of major depressive disorder and this was more commonly prescribed to the 
non-cancer patients (Australian Medicines Handbook, 2015). Conversely, mirtazapine is well 
known for its benefits of appetite and sleep and was frequently prescribed to the cancer 
patients. However, these medicines are more commonly associated with patients’ suicidal 
thoughts and behaviour (Australian Medicines Handbook, 2015). Future studies should 
investigate this further and assess whether additional psychotherapy may assist these patients 
to improve in their depressive symptoms (Sharpe et al., 2014).      
Few previous studies investigated the association between comorbid diseases and 
antidepressants uses (Ashbury et al., 2003; Ng et al, 2013b & Jones at al., 2015). In our study, 
fewer cancer than non-cancer patients had more than seven chronic disease conditions. The 
majority of the sample experienced several comorbidities such as hypertension, diabetes, 
arthritis, GORD and these may affect the pharmacological treatment of depression. A review 
showed that patients with comorbidities including myocardial infarction, stroke, diabetes, 
cancer, and rheumatoid arthritis are less likely to respond to antidepressant treatment due to 
their comorbidities (Iosifescu et al., 2004). This needs to be taken into account when 
prescribing antidepressants to multimorbid patient populations such as those involved in this 
study. 
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This study found some evidence for drug-drug interactions of concern. A number of cancer 
patients (n= 23) could have potentially suffered one or more potential drug-drug interaction 
compared to 18 non-cancer patients, however, only seven patients actually had notes about 
adverse events occurring in their patient record. From the retrospective data it is not possible 
to discern whether because adverse events actually did not occur or may be underreporting of 
such events, and future prospective studies are needed to better clarify this question. Major 
drug interactions may occur between escitalopram and oxycodone and these medications 
were prescribed to two patients simultaneously. Twelve patients were prescribed with 
escitalopram and oxycodone which should not be used simultaneously due to risk of 
serotonin syndrome. A number of antidepressants are known to reduce the effectiveness of 
anticancer drugs including tamoxifen, doxorubicin, irinotecan, gefitinib, imatinib and so on 
(Chan et al., 2012). In this study none of the cancer patients were prescribed such 
combinations, but the proportion of cancer patients with each individual cancer was very 
small thus limiting the likelihood to detect such combined prescribing. 
3.8.2 Strength of the study  
 
This study provided detailed prescription characteristics of antidepressants taken by cancer or 
non-cancer inpatients including type, dose, variation of dose from recommended therapeutic 
dose, probable drug-drug interactions. The case-control design identified factors that impact 
on the prescription practices for cancer patients, including reason for prescribing 
antidepressant, patient status, co-morbidities, and suicidal ideation. Approximately 33% 
(n=75/226) of cancer inpatients prescribed with antidepressants within 12 months of cancer 
diagnosis treated at the RBWH in the department of Pharmacy or between January 2014 and 
July 2015 were included in our study. This pilot retrospective case-control study thus 
provided a contemporary overview of prescription characteristics of antidepressants to cancer 
and non-cancer patients in Australia.  
The case-control sample was chosen, as it is the most appropriate design for addressing the 
research aims- 
• Identified a matched sample which allowed extracting differences in antidepressant 
prescribing pattern between cancer and non-cancer patients. 
• Detailed prescription characteristic of antidepressants- type, dose, variation of dose from 
recommended therapeutic dose, probable drug-drug interactions. 
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• Included a large proportion of the available patients from two wards.  
• Provided the groundwork for a future national larger study on medication practices in 
mental health for cancer patients.  
3.8.3 Limitations of the study 
 
Our study has a number of limitations. We intended to comprehensively describe the 
prescription practices of antidepressants to cancer and non-cancer inpatients and whether 
these were provided for mental health or physical health reasons. The main limitation of this 
study was that many patients were referred from other hospitals to this tertiary centre, and 
medical as well as prescription information may have been reported elsewhere. However, for 
a considerable number of patients (n= 32), we could not identify a detailed report of reason 
for antidepressants prescription to the patients, or the starting date of antidepressants.  It was 
also frequently not possible to identify the prescriber characteristics for antidepressant 
prescription including who first prescribed the antidepressant, or reasons for changing dose 
and type of antidepressant. The exact starting date of antidepressants could only be identified 
for five cancer patient from the database system. Due to under-reporting of starting date of 
antidepressants and prescriber characteristics, we could not identify whether patients took 
antidepressants before or after diagnosis of cancer, the detailed reason for prescription of 
antidepressants or whether suicidal ideation occurred before or after the prescription of 
antidepressants. 
In some instance, there could be overlap of indication of antidepressants for the treatment of 
depression and other mental health condition or physical side effect. We could identify 
indication of antidepressant from prescription recorded by health care professionals only 
from 12% (n=13/90) of cancer and 2% (n= 2/95) of non-cancer inpatients. This limitation 
could be resolved in a future prospective study by regularly conducting a diagnostic test to 
determine depression of the study; however, in the current study diagnostics tests to 
determine depression were rarely recorded in the hospital database system. Several other 
results of this study also require confirmation in future prospective data collection; for 
example, whether adverse events occur if medications are given simultaneously despite such 
combinations not recommended, or whether patients improve in their depressive symptoms 
despite lower than recommended dose of antidepressants.  
54 
 
Lack of documentation about regular follow-up or social support as well as information about 
family history of depression were also identified from the database system. The 
corresponding letter from the health care professionals referring the patients to the hospital 
mainly reported the cancer related information. The PHQ-2 was conducted frequently, but not 
always during patients’ hospital admission for cancer treatment, but often was not repeated 
limiting the assessment whether the antidepressants led to a reduction in symptomatology.   
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Chapter 4: Recommendations and conclusions 
 
4.1 Public health significance 
 
Study one provided a thorough literature review at international level. This will allow 
researchers as well as health care professionals, not only from Australia, but also from other 
countries to obtain a succinct overview of prescription practices of antidepressants over more 
than four decades. The meta-analysis showed a pooled estimate of prescription prevalence of 
antidepressants to cancer patients of 15.6% (95%CI= 13.3%-18.3%). Through its subgroup 
analysis by study and patient characteristics, the result also shows that prescriptions of 
antidepressants were more common in female (22.6%; 95% CI= 16.0-31.0) or breast cancer 
patients (n= 6/7, 22.6%; 95% CI= 16.0-30.9). It also found a greatly reduced frequency of 
prescribing in Asian countries. Data from Australia was limited with only one eligible study 
identified. These findings indicate the importance of further public health research to better 
understand differentials in prescribing and follow-up through future in-depth studies in 
Australia. The lack of detailed data in the literature especially on the exact dose or length of 
time antidepressants were prescribed to cancer patients also indicated the presence of 
significant knowledge gaps that need to be addressed in future work.     
Study two was conducted at one major hospital. It has delivered a significant contribution to 
the public health in Queensland as well as Australia by describing in detail the prescription 
practices of antidepressants to cancer and non-cancer patients. The results of this study have 
provided the major features associated with the mental health treatment of cancer patients for 
health care professionals. Key findings include an overview of prescription practices of 
antidepressants and potential risks of prescription to cancer patients. This study also describes 
prescription characteristics of antidepressants including type, variation of dose, and number 
antidepressants prescribed which is important for the health care professionals regarding the 
current practice of antidepressants. Moreover, study findings also indicate the importance of 
follow-up of mental health and pharmacological treatment, awareness of the prescription 
status of newly diagnosed cancer patients and that their prescription is suitably adjusted to 
address changes in mental health wellbeing. 
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4.2 Future research 
 
The combined results of study 1 and 2 indicate that the prescription practices of 
antidepressants for the treatment of depression in cancer patients in Australia is under-
researched and prospective cohort studies are required in the future to address the following 
research gaps:    
 Besides the data collected in the present case-control study (Appendix G: Data collection 
form), it would be beneficial to also determine other factors including knowledge about 
the benefits of taking antidepressants of cancer patients, medication adherence, impact on 
their quality of life, relevance and changes in clinical depression tests such as the PHQ 
and follow-up by survey or patient self-reported questionnaire.  
 The prevalence of antidepressants or other medicines prescribed for the treatment of 
depression to cancer patients diagnosed with common type of cancer- breast, lung, 
prostate or bowel needs to be studied in greater detail to determine how well this 
treatment is used for mental health issues and whether it is effective.  
 It is also necessary to determine the mental health status of long-term cancer survivors 
and their antidepressants prescription treatment pattern. 
 Due to identifying a high prescription prevalence of antidepressants to breast cancer or 
females in the meta-analysis, more research in women diagnosed with gynaecological 
cancer is also essential in Australia to identify the impact of cancer diagnosis on females 
and treatment of mental health in these patients.  
 Besides the potential of adverse effects and drug-drug interactions of antidepressant with 
anticancer treatments, some researchers have raised concern that antidepressants may 
cause development of cancer or increase the mortality from cancer (Nordenberg et al., 
1999). Research in this area has been conducted widely in other countries (Cotterchio et 
al., 2000; Ashbury et al., 2010; Cronin-Fenton et al., 2011; Walker et al., 2011) and 
should be considered for future research projects in Australia too.  
 Review of prescription characteristics of antidepressants that are used for the treatment of 
mental health issues other than depression to cancer patients could identify if these 
medications have the desired effect and whether they are being ceased when the symptom 
burden is reduced. 
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4.3 Conclusions 
 
In conclusions, antidepressants are commonly prescribed in the treatment of depression and 
other unidentified problems in cancer patients. It may be of concern that the reason for a 
significant proportion of antidepressant prescriptions to cancer patients could not be 
identified from the clinical or prescription records, especially given their potential for adverse 
effects and drug-drug interaction with other medicines. With better treatments and earlier 
detection the survival rate of cancer patient has increased significantly over the past decades; 
however, comorbidity of depression threatens the quality of life of cancer patients. 
Prospective cohort studies may be the next logical step to determine the current knowledge 
gaps and limitations identified from the systematic literature search and retrospective study 
conducted for this thesis. Attention needs to be taken for the correct prescription practices of 
antidepressants. Prospective studies may also be useful not only to thoroughly assess the 
present status of mental health of cancer patients but also to show the value of regular follow-
up of depression status after prescribing antidepressants. Patient self-administered 
questionnaires may be a suitable data collection method to ascertain not only the patients’ 
wellbeing but also prescriber characteristics and may also overcome missing data identified 
from the present research method.  
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Appendix A: Supplementary Tables 
 
Supplementary Table 2.1: Sensitivity Analysis 
 
Name of study 
Prevalence of 
antidepressant and total 
number of sample 
Pooled estimate after sensitivity 
analysis 
Weight 
(%) 
Chaturvedi et al., 1994
37
 67% (n= 146) 14.8% (95% CI; 12.5%-17.3%) 2.51% 
Findley et al., 2012
40
 57.7% (n=865) 14.9% (95% CI; 12.6%-17.4%) 2.69% 
Derogatis et al., 1979
31
 0.5% (n=1,579) 16.5% (95% CI; 14%-19.4%) 2.01% 
Yokoyama et al., 2012
42
 1% (n=194) 16% (95% CI; 13.6%-18.7%) 1.12% 
Zhao et al., 2014
23
 1.3% (n=460) 16.2% (95% CI; 13.7%-19%) 1.84% 
Walker et al., 2014
38
 1.75% (n= 21,151) 16.6% (95% CI; 14.3%- 19.1%) 2.71% 
Sensitivity analysis was conducted to determine the robustness of pooled estimate. The studies selected 
for sensitivity analysis according to the highest
37,40
, lowest
23,31,3842 
 prevalence rate of antidepressants containing 
study which resulted various pooled estimates with different weights. Among these studies Chaturvedi and 
colleagues
37
 and Walker and colleagues
38
 significantly influenced the pooled estimate of the meta-analysis.   
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Supplementary Table 2.2: Alternate grouping of studies by decade  
 
Decade 
Number of 
study 
Pooled estimate after sub-group analysis Heterogeneity (%) 
1976-1985 3 0.028(0.013-0.058) 97.29 
1986-1995 2 0.259(0.123-0.466) 98.44 
1996-2005 5 0.210(0.134-0.314) 94.32 
2006-2015 28 0.159(0.131-0.191) 99.75 
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Supplementary Table 2.3: Quality assessment and bias risk scale 
 
Quality Assessment Scale Bias Risk Scale 
1=Low quality 
2= Low-to-medium quality 
3= Medium-to-high quality 
4= High quality 
0= No risk 
1= Low bias risk 
2= Low-to-medium bias risk 
3= Medium-to-high bias risk 
4= High bias risk 
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Supplementary Table 2.4: Trends of prescription of antidepressants over time 
 
Year
1
 Prescription of Antidepressants
2
 Reference 
No 
1979 TCA-Amitriptyline, Imipramine 31 
1981-1982 Amitriptyline, Imipramine 32 
1985 Doxepine, Amoxapine, Amitriptyline, Imipramine 41 
1987 Amitriptyline, Desipramine, Maprotiline 39 
1993-2005 SSRI, SNRI 
Paroxetine, Sertraline, Citalopram, Venlafaxine, Fluoxetine, 
Fluvoxamine 
52 
1994 Dothiepin(25-225mg), Mianserin(10-30mg), Amitriptyline(50-
175mg), Clomipramine(50-150mg), Other 
37 
1994-2006 Amitriptyline, Paroxetine, Venlafaxine, Citalopram, Mirtazapine, 
Others 
48 
1995 SSRI, TCA, MAO 
Dothiepin-25mg/day, Fluoxetine,  Paroxetine, Sertraline, 
Flupenthixol,  Phenelzine 
33 
1997 SSRI- Nefazodone & other 30 
2000-2005 MAO, SSRI, SNRI, TCA 40 
2001-2004 SSRI, TCA, Serotonin modulators, MAOI, Other 49 
2002 Paroxetine, Amitriptyline,  Fluoxetine, Citalopram, Trazodone 28 
2003-2004 Mirtazapine(15mg), Citalopram (10mg), Escitalopram (5mg), 
Fluvoxamine, Paroxetine 
62 
2005-2006 TCA, SSRI, TeCA, MAOI, SNRIs, Other 
Citalopram, Escitalopram, Mianserin, Mirtazapine 
47 
2005-2009 SSRI, TCA, Other 56 
2005-2010 TCA, Other 43 
2005-2011 SSRI, SNRI, TCA, MAO 44 
2006 Mirtazapine, Citalopram, Paroxetine, Venlafaxine, Amitriptyline, 
Fluoxetine, Duloxetine, Others 
28 
2006-2008 SSRI/SNRIs,TCA 49 
2007 SSRI, TCA, Venlafaxine, 58 
2007-2009 SSRI, NSSA 61 
2008-2011 Amitriptyline, Citalopram, Clomipramine, Dosulepin, Doxepin, 
Duloxetine, Escitalopram, Fluoxetine, Flupentixol, Fluvoxamine, 
Imipramine, Lofepramine, Mirtazapine, Nortriptyline, Paroxetine, 
Phenelzine, Reboxetine, Sertraline, 
Trazodone, Trimipramine, Venlafaxine. 
38 
2009 Mirtazapine, Escitalopram, Citalopram, Paroxetine, 
Amitriptyline, Trazodone, Duloxetine, Venlafaxine, Fluoxetine, 
Others 
28 
1
Year indicated timeline present in the study or year of publication. 
2
Prescription of antidepressants in italic font 
indicated the highest to lowest number of antidepressant user in the article. 
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Supplementary Table 2.5: Alternate grouping of studies by study period 
 
Decade* Reference number 
Pooled estimate after sub-group 
analysis 
Heterogeneity (%) 
1971-1980 31 0.005(0.001-0.018)  
1981-1990 32, 39 0.062(0.027-0.134) 88.4 
1991-2000 
29, 30, 33, 35, 37, 41, 
48, 52,  
0.222(0.159-0.299) 98.88 
2001-2010 
21, 22, 28, 34, 36, 38, 
40, 42, 43, 44, 45, 47, 
49-51, 53-62 
0.167(0.138-0.200) 99.69 
>2011 23, 46 0.076(0.033-0.163) 97.98 
*
Decade indicated study period present in the study or year of publication. 
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Supplementary Table 2.6: Type and dose of antidepressants prescription to cancer and 
non-cancer patients in the hospital 
  Cancer Non-cancer 
  
Depressive 
patient 
(n= 50) 
Other 
mental 
health 
problem 
(n= 8) 
No 
information 
of mental 
health 
problem 
(n= 17) 
Depressive 
patient  
(n= 59) 
Other 
mental 
health 
problem  
(n= 11) 
No 
information 
of mental 
health 
problem  
(n= 5) 
Antidepressant 
prescription (n) 
59 10 21 75 13 7 
Type & dose of antidepressant
1
 
Amitriptyline 
      
<75mg 2 - 3 3 1 2 
75mg - - - 1 - - 
Citalopram 
      
<20mg - - - 2 1 - 
20mg 2 - 1 2 - - 
>20mg 1 - - - - - 
Desvenlafaxine 
      
50mg 2 - 2 6 1 - 
>50mg 1 - - 9 1 - 
Dothiepin 
      
75mg 1 1 - 1 - - 
Doxepine 
      
<100mg - 2 - 1 - - 
Duloxetine 
      
<60mg 2 - - 2 - - 
60mg 5 - 2 5 1 1 
>60mg 2 - - - - - 
Escitalopram  
      
10mg 4 1 - 2 1 - 
>10mg 4 - - 6 - 1 
Fluoxetine 
      
20mg 4 - 1 2 - - 
>20mg - - 2 4 1 - 
Fluvoxamine 
      
<100mg 1 - - - - - 
100mg 1 - 1 - - - 
>100mg 1 - - 2 - - 
Meclobemide 
      
<300mg 1 - - - - - 
>300mg 1 - - - - - 
Mirtazapine 
      
<30mg 5 2 2 - - 1 
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30mg 3 3 3 7 - 1 
>30mg 3 - 1 4 1 1 
Nortriptyline 
      
<30mg - - - 1 - - 
30mg - - - 1 - - 
Paroxetine 
      
20mg 2 1 - 2 1 - 
>20mg 
 
- - 2 1 - 
Sertraline 
      
>20mg 4 - 1 6 - - 
Venlafaxine 
      
<100mg 2 - 2 3 1 - 
>100mg 5 - - 1 2 - 
1
indicated type and dose of antidepressants according to Anatomical Therapeutic Chemical (ATC) Classification 
System. Italicized entries indicated the recommended dose. 
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Appendix B: PHQ-2 Screen 
 
Mood: Over the past 2 weeks, how often have you been bothered by the following problems? 
Little interest or pleasure in doing things? 
Not at all= 0, Several days= 1, More than half of the days 2, Nearly everyday= 3 
 
Feeling down, depressed or hopeless 
Not at all= 0, Several days= 1, More than half of the days 2, Nearly everyday= 3 
 
Total score  
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Appendix C: RBWH HREC Approval Letter 
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Appendix D: QUT HREC Application Approval Letter 
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Appendix E: Public Health Act- Application Approval 
Letter 
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Appendix F: Research Governance Office Application 
Approval Letter 
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Appendix G: Data Collection Form 
 
Clinical Audit Form 
Study: Prescription practices of antidepressants to patients 
Study ID:                                                                 Date: ____/____/2015                                       
Hospital: RBWH                                                     Other Hospital: 
1. Age: 2. Sex:  
o Male                         ○  Female 
3. Patient type: 
o Cancer 
o Non-Cancer 
4. Patient status: 
o Alive 
o Deceased__________________ 
5. Country of origin: 6. Living status: 
7. Religion: 
o No 
o Does not wish to be visited 
8. Insurance: 
o Yes- 
o No 
9. Alcohol status: 
o Current- 
o Ex-alcoholic - 
o Never -  
10. Smoking status:  
o Current- 
o Ex-smoker- 
o Never- 
11. Marital status:  
o Married 
o Divorced/ Separated 
o Never married 
12. Employment: 
o Yes 
o ______________ 
o No 
13. Concession status: 14. Other: 
87 
 
 
15. i. Cancer Related Information 
o Date of diagnosis- 
o Type- 
o Stage- 
o Type of Treatment- 
o Chemotherapy 
o Radio-Therapy 
o Both 
15. ii. Cancer Related Information 
o Date of diagnosis- 
o Type- 
o Stage- 
o Type of Treatment- 
o Chemotherapy 
o Radio-Therapy 
o Both 
16. History of depression: 
i. Personal history of depression- 
o Yes,  
o ________________ 
o No 
 
ii. Family history of depression- 
o Yes,  
o _______________ 
o No 
17. Depression related information: 
o Date of diagnosis 
o Symptoms- 
o Referral for counselling/ 
psychotherapy- 
o Yes 
o No 
 
o Who suggested? 
_____________ 
o Who prescribed antidepressants?- 
o Time/Date to start taking 
antidepressant- 
o Not reported 
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18. Comorbidities/Pre-medical disease: 
i. 
ii. 
iii. 
 
iv. 
v. 
vi. 
19. Other psychological problem- 
o Yes,  
o Specify ________________ 
o No 
o Not recorded 
20. Pain risk assessment: Range from 0-10 
o Yes 
o Score______________ 
o No  
o Not recorded 
21. Mood risk assessment test: PHQ-2 
o Yes,  
o Score___________ 
o No 
o Not recorded 
22. Further mental health assessment test- 
o Yes,  
o Score___________ 
o No 
o Not recorded 
23. Allergic reaction- 
o Yes________________________ 
o No known allergy 
o Not recorded 
24. Adverse drug reaction- 
o Yes________________________ 
o No 
o Not recorded 
 
Notes/ Others: 
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Medication Audit Form 
No Date Generic/ Brand name, dose, 
dosage form, Rout of 
administration 
Indication Regular 
(R)/ 
PRN 
Quantity Comments 
1.  
 
 
     
2.  
 
 
     
3.  
 
 
     
4.  
 
 
     
5.  
 
 
     
6.  
 
 
     
7.  
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8.  
 
 
     
9.  
 
 
     
10.  
 
 
     
11.  
 
 
     
12.  
 
 
     
13.  
 
 
     
14.  
 
 
     
15.  
 
 
     
16.       
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17. 
 
 
      
18. 
 
 
      
19. 
 
 
      
20. 
 
 
      
21. 
 
 
      
22. 
 
 
      
23. 
 
 
      
24. 
 
 
      
 
92 
 
Ceased Medication 
No Date Generic/ Brand name, dose, 
dosage form, Rout of 
administration 
Reason Comments 
1.   
 
 
   
2.  
 
 
   
3.  
 
 
   
4.  
 
 
   
5.  
 
 
   
6.  
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Note/ Others: 
 
 
